Form 10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

 

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 1, 2012

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     .

Commission file number 1-5353

 

 

TELEFLEX INCORPORATED

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   23-1147939

(State or other jurisdiction of

incorporation or organization)

  (I.R.S. employer identification no.)
155 South Limerick Road, Limerick, Pennsylvania   19468
(Address of principal executive offices)   (Zip Code)

(610) 948-5100

(Registrant’s telephone number, including area code)

(None)

(Former Name, Former Address and Former Fiscal Year, If Changed Since Last Report)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   x    Accelerated filer   ¨
Non-accelerated filer   ¨  (Do not check if a smaller reporting company)    Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ¨    No  x

The registrant had 40,865,780 shares of common stock, $1.00 par value, outstanding as of July 20, 2012.

 

 

 


Table of Contents

TELEFLEX INCORPORATED

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED JULY 1, 2012

TABLE OF CONTENTS

 

      Page  
PART I — FINANCIAL INFORMATION   
Item 1:  

Financial Statements (Unaudited):

  
 

Condensed Consolidated Statements of Income for the three and six months ended July 1, 2012 and June 26, 2011

     2   
 

Condensed Consolidated Statements of Comprehensive Income for the three and six months ended July 1, 2012 and June 26, 2011

     3   
 

Condensed Consolidated Balance Sheets as of July 1, 2012 and December 31, 2011

     4   
 

Condensed Consolidated Statements of Cash Flows for the six months ended July 1, 2012 and June 26, 2011

     5   
 

Condensed Consolidated Statements of Changes in Equity for the six months ended July 1, 2012 and June 26, 2011

     6   
 

Notes to Condensed Consolidated Financial Statements

     7   
Item 2:  

Management’s Discussion and Analysis of Financial Condition and Results of Operations

     35   
Item 3:  

Quantitative and Qualitative Disclosures About Market Risk

     44   
Item 4:  

Controls and Procedures

     45   
PART II — OTHER INFORMATION   
Item 1:  

Legal Proceedings

     46   
Item 1A:  

Risk Factors

     46   
Item 2:  

Unregistered Sales of Equity Securities and Use of Proceeds

     46   
Item 3:  

Defaults Upon Senior Securities

     46   
Item 5:  

Other Information

     46   
Item 6:  

Exhibits

     47   
SIGNATURES      48   

 

1


Table of Contents

PART I FINANCIAL INFORMATION

 

Item 1. Financial Statements

TELEFLEX INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

 

    Three Months Ended     Six Months Ended  
    July 1,
2012
    June 26,
2011
    July 1,
2012
    June 26,
2011
 
    (Dollars and shares in thousands, except per share)  

Net revenues

  $ 383,332      $ 381,168      $ 763,899      $ 726,749   

Cost of goods sold

    198,968        199,817        395,421        383,351   
 

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

    184,364        181,351        368,478        343,398   

Selling, general and administrative expenses

    105,951        109,838        218,087        211,548   

Research and development expenses

    13,702        12,455        25,255        23,486   

Goodwill impairment

    —          —          332,128        —     

Restructuring and other impairment charges

    321        3,176        (1,004     3,771   

Gain on sales of businesses and assets

    (332     —          (332     —     
 

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations before interest, loss on extinguishments of debt and taxes

    64,722        55,882        (205,656     104,593   

Interest expense

    18,240        15,785        36,451        31,931   

Interest income

    (506     (253     (984     (358

Loss on extinguishments of debt

    —          816        —          15,413   
 

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations before taxes

    46,988        39,534        (241,123     57,607   

Taxes (benefit) on income (loss) from continuing operations

    (278     8,436        (4,276     13,009   
 

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations

    47,266        31,098        (236,847     44,598   
 

 

 

   

 

 

   

 

 

   

 

 

 

Operating income (loss) from discontinued operations (including gain (loss) on disposal of $2,264 for the three and six month periods in 2012 and ($4,504) and $52,269 for the three and six month periods in 2011, respectively)

    (8,049     (3,593     (7,120     61,117   

Taxes (benefit) on income (loss) from discontinued operations

    (3,682     (6,982     (3,358     (6,966
 

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from discontinued operations

    (4,367     3,389        (3,762     68,083   
 

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss)

    42,899        34,487        (240,609     112,681   

Less: Income from continuing operations attributable to noncontrolling interest

    286        258        513        481   

Income from discontinued operations attributable to noncontrolling interest

    —          159        —          318   
 

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) attributable to common shareholders

  $ 42,613      $ 34,070      $ (241,122   $ 111,882   
 

 

 

   

 

 

   

 

 

   

 

 

 

Earnings per share available to common shareholders:

       

Basic:

       

Income (loss) from continuing operations

  $ 1.15      $ 0.76      $ (5.82   $ 1.09   

Income (loss) from discontinued operations

    (0.11     0.08        (0.09     1.69   
 

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss)

  $ 1.04      $ 0.84      $ (5.91   $ 2.78   
 

 

 

   

 

 

   

 

 

   

 

 

 

Diluted:

       

Income (loss) from continuing operations

  $ 1.14      $ 0.75      $ (5.82   $ 1.09   

Income (loss) from discontinued operations

    (0.10     0.08        (0.09     1.66   
 

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss)

  $ 1.04      $ 0.83      $ (5.91   $ 2.75   
 

 

 

   

 

 

   

 

 

   

 

 

 

Dividends per common share

  $ 0.34      $ 0.34      $ 0.68      $ 0.68   

Weighted average common shares outstanding:

       

Basic

    40,834        40,536        40,801        40,297   

Diluted

    41,076        40,872        40,801        40,648   

Amounts attributable to common shareholders:

       

Income (loss) from continuing operations, net of tax

  $ 46,980      $ 30,840      $ (237,360   $ 44,117   

Income (loss) from discontinued operations, net of tax

    (4,367     3,230        (3,762     67,765   
 

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss)

  $ 42,613      $ 34,070      $ (241,122   $ 111,882   
 

 

 

   

 

 

   

 

 

   

 

 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

2


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

 

    Three Months Ended     Six Months Ended  
    July 1,
2012
    June 26,
2011
    July 1,
2012
    June 26,
2011
 
    (Dollars in thousands)  

Net income (loss)

  $ 42,899      $ 34,487      $ (240,609   $ 112,681   

Other comprehensive income (loss), net of tax:

       

Foreign Currency:

       

Foreign currency translation continuing operations adjustments, net of tax ($(13,397), $(25), $(9,184), $2,323 for the three and six month periods, respectively)

    (66,391     13,627        (35,708     61,851   

Foreign currency translation discontinued operations adjustments

    —          432        —          2,504   

Foreign currency translation divestiture of Marine

    —          —          —          (33,424
 

 

 

   

 

 

   

 

 

   

 

 

 

Foreign currency translation, net of tax

    (66,391     14,059        (35,708     30,931   
 

 

 

   

 

 

   

 

 

   

 

 

 

Pension and Other Postretirement Benefits Plans:

       

Prior service cost recognized in net periodic cost, net of tax ($(3), $(3), $(5), $(5) for the three and six month periods, respectively)

    (4     (4     (7     (8

Transition obligation recognized in net periodic cost, net of tax ($9, $11, $18, $21 for the three and six month periods, respectively)

    16        17        31        34   

Curtailments arising during the period, net of tax ($(50) for the three and six month periods in 2012)

    (84     —          (84     —     

Settlements arising during the period, net of tax ($41 for the three and six month periods in 2012)

    70        —          70        —     

Unamortized gain arising during the period, net of tax ($1 and $2,884 for the three and six month periods in 2011, respectively)

    —          8        —          4,690   

Net loss recognized in net periodic cost, net of tax ($604, $369, $1,209, $769 for the three and six month periods, respectively)

    1,104        654        2,209        1,358   

Discontinued operations, net of tax ($(14) for the six month period in 2011)

    —          —          —          (37

Divestiture of Marine, net of tax ($4,612 for the six month period in 2011)

    —          —          —          8,427   

Foreign currency translation, net of tax ($94, $9, $44, $(173) for the three and six month periods, respectively)

    256        28        117        (455
 

 

 

   

 

 

   

 

 

   

 

 

 

Pension and other postretirement benefits plans adjustment, net of tax

    1,358        703        2,336        14,009   
 

 

 

   

 

 

   

 

 

   

 

 

 

Derivatives qualifying as hedges:

       

Unrealized gain (loss) on derivatives arising during the period, net of tax ($(334), $(511), $(13), ($280) for the three and six month periods, respectively)

    (536     (820     157        (981

Reclassification adjustment on derivatives included in net income, net of tax ($1,391, $1,410, $2,478, $2,621 for the three and six month periods, respectively)

    2,382        2,396        4,149        4,321   

Discontinued operations, net of tax ($(89) and $(8) for the three and six month periods in 2011, respectively)

    —          (157     —          (15
 

 

 

   

 

 

   

 

 

   

 

 

 

Derivatives qualifying as hedges, net of tax

    1,846        1,419        4,306        3,325   
 

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss), net of tax

    (63,187     16,181        (29,066     48,265   
 

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss)

    (20,288     50,668        (269,675     160,946   

Less: comprehensive income attributable to noncontrolling interest

    44        434        349        810   
 

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss) attributable to common shareholders

  $ (20,332   $ 50,234      $ (270,024   $ 160,136   
 

 

 

   

 

 

   

 

 

   

 

 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

3


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

     July 1,
2012
     December 31,
2011
 
     (Dollars in thousands)  
ASSETS      

Current assets

     

Cash and cash equivalents

   $ 544,991       $ 584,088   

Accounts receivable, net

     275,166         286,226   

Inventories, net

     284,555         298,775   

Prepaid expenses and other current assets

     24,813         33,405   

Prepaid taxes

     29,690         28,846   

Deferred tax assets

     36,526         41,014   

Assets held for sale

     53,890         7,902   
  

 

 

    

 

 

 

Total current assets

     1,249,631         1,280,256   

Property, plant and equipment, net

     253,684         251,912   

Goodwill

     1,095,591         1,438,542   

Intangible assets, net

     938,129         879,787   

Investments in affiliates

     1,669         2,008   

Deferred tax assets

     275         278   

Other assets

     67,843         71,320   
  

 

 

    

 

 

 

Total assets

   $ 3,606,822       $ 3,924,103   
  

 

 

    

 

 

 
LIABILITIES AND EQUITY      

Current liabilities

     

Current borrowings

   $ 4,700       $ 4,986   

Accounts payable

     65,471         67,092   

Accrued expenses

     83,177         78,160   

Payroll and benefit-related liabilities

     58,921         64,386   

Derivative liabilities

     1,669         633   

Accrued interest

     9,155         10,960   

Income taxes payable

     12,911         21,084   

Current liability for uncertain tax positions

     3,910         22,656   

Deferred tax liabilities

     1,011         1,050   

Liabilities held for sale

     1,749         —     
  

 

 

    

 

 

 

Total current liabilities

     242,674         271,007   

Long-term borrowings

     959,945         954,809   

Deferred tax liabilities

     397,454         420,833   

Pension and postretirement benefit liabilities

     182,461         194,984   

Noncurrent liability for uncertain tax positions

     60,226         61,688   

Other liabilities

     72,048         37,999   
  

 

 

    

 

 

 

Total liabilities

     1,914,808         1,941,320   

Commitments and contingencies

     

Total common shareholders’ equity

     1,689,470         1,980,588   

Noncontrolling interest

     2,544         2,195   
  

 

 

    

 

 

 

Total equity

     1,692,014         1,982,783   
  

 

 

    

 

 

 

Total liabilities and equity

   $ 3,606,822       $ 3,924,103   
  

 

 

    

 

 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

4


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

    Six Months Ended  
    July 1, 2012     June 26, 2011  
    (Dollars in thousands)  

Cash Flows from Operating Activities of Continuing Operations:

   

Net income (loss)

  $ (240,609   $ 112,681   

Adjustments to reconcile net income to net cash provided by operating activities:

   

Loss (income) from discontinued operations

    3,762        (68,083

Depreciation expense

    17,148        20,326   

Amortization expense of intangible assets

    21,202        21,375   

Amortization expense of deferred financing costs and debt discount

    7,098        6,642   

Loss on extinguishments of debt

    —          15,413   

Stock-based compensation

    4,003        965   

Impairment of investments in affiliates

    —          3,061   

Gain on sales of businesses and assets

    (332     —     

Goodwill impairment

    332,128        —     

Deferred income taxes, net

    (21,480     941   

Other

    (2,771     658   

Changes in operating assets and liabilities, net of effects of acquisitions and disposals:

   

Accounts receivable

    (13,225     (36,957

Inventories

    2,698        (18,058

Prepaid expenses and other current assets

    8,476        (3,707

Accounts payable and accrued expenses

    (5,192     (1,923

Income taxes receivable and payable, net

    (23,668     (15,561
 

 

 

   

 

 

 

Net cash provided by operating activities from continuing operations

    89,238        37,773   
 

 

 

   

 

 

 

Cash Flows from Investing Activities of Continuing Operations:

   

Expenditures for property, plant and equipment

    (28,893     (15,132

Proceeds from sales of businesses and assets, net of cash sold

    17,155        100,916   

Payments for businesses and intangibles acquired, net of cash acquired

    (62,627     (30,570
 

 

 

   

 

 

 

Net cash (used in) provided by investing activities from continuing operations

    (74,365     55,214   
 

 

 

   

 

 

 

Cash Flows from Financing Activities of Continuing Operations:

   

Proceeds from long-term borrowings

    —          515,000   

Repayment of long-term borrowings

    —          (455,800

Decrease in notes payable and current borrowings

    (707     —     

Proceeds from stock compensation plans

    4,091        30,577   

Dividends

    (27,756     (27,438

Debt extinguishment, issuance and amendment fees

    —          (19,058
 

 

 

   

 

 

 

Net cash (used in) provided by financing activities from continuing operations

    (24,372     43,281   
 

 

 

   

 

 

 

Cash Flows from Discontinued Operations:

   

Net cash (used in) provided by operating activities

    (8,191     13,151   

Net cash used in investing activities

    (2,121     (1,386
 

 

 

   

 

 

 

Net cash (used in) provided by discontinued operations

    (10,312     11,765   
 

 

 

   

 

 

 

Effect of exchange rate changes on cash and cash equivalents

    (19,286     9,324   
 

 

 

   

 

 

 

Net (decrease) increase in cash and cash equivalents

    (39,097     157,357   

Cash and cash equivalents at the beginning of the period

    584,088        208,452   
 

 

 

   

 

 

 

Cash and cash equivalents at the end of the period

  $ 544,991      $ 365,809   
 

 

 

   

 

 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

5


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited)

 

    Common Stock     Additional
Paid in
Capital
    Retained
Earnings
    Accumulated
Other
Comprehensive
Income
    Treasury
Stock
    Noncontrolling
Interest
    Total
Equity
 
    Shares     Dollars           Shares     Dollars      
    (Dollars and shares in thousands, except per share)  

Balance at December 31, 2010

    42,245      $ 42,245      $ 349,156      $ 1,578,913      $ (51,880     2,250      $ (135,058   $ 3,902      $ 1,787,278   

Net income

          111,882              799        112,681   

Cash dividends ($0.68 per share)

          (27,438             (27,438

Comprehensive income

            48,254            11        48,265   

Shares issued under compensation plans

    609        609        25,503            (55     3,315          29,427   

Deferred compensation

        (39         (4     163          124   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at June 26, 2011

    42,854      $ 42,854      $ 374,620      $ 1,663,357      $ (3,626     2,191      $ (131,580   $ 4,712      $ 1,950,337   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

    Common Stock     Additional
Paid in

Capital
    Retained
Earnings
    Accumulated
Other
Comprehensive

Income
    Treasury
Stock
    Noncontrolling
Interest
    Total
Equity
 
    Shares     Dollars           Shares     Dollars      
    (Dollars and shares in thousands, except per share)  

Balance at December 31, 2011

    42,923      $ 42,923      $ 380,965      $ 1,847,106      $ (159,353     2,183      $ (131,053   $ 2,195      $ 1,982,783   

Net income (loss)

          (241,122           513        (240,609

Cash dividends ($0.68 per share)

          (27,756             (27,756

Comprehensive income

            (28,902         (164     (29,066

Shares issued under compensation plans

    81        81        4,091            (39     2,384          6,556   

Deferred compensation

        (10         (4     116          106   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at July 1, 2012

    43,004      $ 43,004      $ 385,046      $ 1,578,228      $ (188,255     2,140      $ (128,553   $ 2,544      $ 1,692,014   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

6


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1—Basis of presentation

We prepared the accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated on the same basis as our annual consolidated financial statements.

In the opinion of management, our financial statements reflect all adjustments, which are of a normal recurring nature, necessary for a fair statement of financial statements for interim periods in accordance with U.S. generally accepted accounting principles (GAAP) and with Rule 10-01 of SEC Regulation S-X, which sets forth the instructions for financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.

In accordance with applicable accounting standards, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in our annual consolidated financial statements. The year-end condensed balance sheet data was derived from audited financial statements, but, as permitted by Rule 10-01 of SEC Regulation S-X, does not include all disclosures required by GAAP for complete financial statements. Accordingly, our quarterly condensed consolidated financial statements should be read in conjunction with the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2011.

Certain reclassifications of prior year information have been made to conform to the current year’s presentation. In the first quarter of 2012, the Company changed its segment reporting from a single reportable segment to four reportable segments. Three of the four reportable segments are geographically based: North America, EMEA (representing the Company’s operations in Europe, the Middle East and Africa) and AJLA (representing Asian and Latin American operations). The Company’s fourth reportable segment is comprised of the Company’s Original Equipment Manufacturer and Development Services (“OEM”) businesses. See Note 14 for a discussion of the Company’s segments. In addition, in the first quarter of 2012, the Company changed the number of its reporting units. In 2011, the Company had six reporting units comprised of North America, EMEA, OEM and three reporting units in the AJLA segment. In 2012, the Company changed its North America reporting unit structure from a single reporting unit to five reporting units comprised of Vascular, Anesthesia/Respiratory, Cardiac, Surgical and Specialty. As a result of the change in the North America reporting unit structure, the Company was required to conduct a goodwill impairment test of each of the North American reporting units and determined that the goodwill of three of the reporting units was impaired. As a result, the Company recorded a goodwill impairment charge of $332 million in the first quarter of 2012. See Note 5 for a discussion of the goodwill impairment.

As used in this report, the terms “we,” “us,” “our,” “Teleflex” and the “Company” mean Teleflex Incorporated and its subsidiaries, unless the context indicates otherwise. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year.

Note 2—New accounting standards

The Company adopted the following new accounting standards as of January 1, 2012, the first day of its 2012 fiscal year:

Amendment to Fair Value Measurement: In May 2011, the Financial Accounting Standards Board (“FASB”) revised the fair value measurement and disclosure requirements so that the requirements under GAAP and International Financial Reporting Standards (“IFRS”) are the same. The guidance clarifies the

 

7


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

FASB’s intent about the application of existing fair value measurements and requires enhanced disclosures, most significantly related to unobservable inputs used in a fair value measurement that is categorized within Level 3 of the fair value hierarchy. The guidance became effective prospectively during interim and annual periods beginning after December 15, 2011.

Amendment to Comprehensive Income: In June 2011, the FASB amended guidance relating to the presentation of comprehensive income within an entity’s financial statements. Under the guidance, an entity has the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income in a single continuous statement or in two separate but consecutive statements. The amended guidance eliminates the previously available option of presenting the components of other comprehensive income as part of the statement of changes in equity. In addition, an entity is required to present adjustments on the face of the financial statements for items that are reclassified from other comprehensive income to net income in the statement where the components of net income and the components of other comprehensive income are presented. The amendment became effective for fiscal years beginning after December 15, 2011 and is applied retrospectively, with the exception of the requirement to present reclassification adjustments from other comprehensive income to net income on the face of the financial statements, which has been deferred pending further deliberation by the FASB.

Note 3—Acquisitions

The Company made the following acquisitions during 2012, all of which were accounted for as business combinations:

 

   

On June 22, 2012, the Company acquired Hotspur Technologies, a developer of catheter-based technologies designed to restore blood flow in patients with obstructed vessels. The acquisition of this business complements the dialysis access product line in the Company’s Cardiac Care division. The Company paid $15.0 million in cash as initial consideration for the business.

 

   

On May 22, 2012, the Company acquired Semprus BioSciences, a biomedical company that developed a long-lasting, covalently bonded, non-leaching polymer designed to reduce infections and thrombus related complications. While the Company will explore opportunities to apply this technology to a broad array of its product offerings, the initial focus for the technology will be with respect to vascular devices within the Company’s Critical Care division. The Company paid $30.0 million in cash as initial consideration for the business.

 

   

On May 3, 2012, the Company acquired substantially all of the assets of Axiom Technology Partners, LLC, constituting its EFx laparoscopic fascial closure system, which is designed for the closure of abdominal trocar defects through which access ports and instruments were used during laparoscopic surgeries. The acquisition of this business complements the surgical closure product line in the Company’s Surgical Care division. The Company paid $7.5 million in cash as initial consideration for the business.

 

   

On April 5, 2012, the Company acquired the EZ-Blocker product line, a single-use catheter used to perform lung isolation and one-lung ventilation. The acquisition of this product line complements the Anesthesia product portfolio in the Company’s Critical Care division. The Company paid $3.3 million in cash as initial consideration for the business.

The total fair value of consideration for the acquisitions is estimated at $111.9 million, which includes the initial payments of $55.8 million in cash and the estimated fair value of the contingent consideration to be paid to the sellers of $56.1 million.

 

8


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

In connection with the acquisitions, the Company agreed to pay aggregate contingent consideration between approximately $61.0 million to $90.0 million, based on the achievement of specified objectives, including regulatory approvals and sales targets. The fair value of each component of contingent consideration was estimated based on the probability of achieving the specified objective using a probability-weighted discounted cash flow model. This fair value measurement is based on significant inputs not observed in the market and thus represents a Level 3 measurement as defined in connection with the fair value hierarchy (see Note 9, “Fair value measurements”). Any future change in the estimated fair value of the contingent consideration will be recognized in selling, general and administrative expenses in the statement of income for the period in which the estimated fair value changes. A change in fair value of the contingent consideration could have a material effect on the Company’s results of operations and financial position for the period in which the change in estimate occurs.

Transaction expenses associated with the acquisitions, which are included in selling, general and administrative expenses on the Condensed Consolidated Statements of Income, were $0.6 million and $0.8 million for the three and six months ended July 1, 2012, respectively. Through July 1, 2012, the Company has recorded an aggregate operating loss of approximately $1.6 million resulting from the acquisitions. The results of operations of the acquired businesses and assets are included in the Condensed Consolidated Statements of Income as of their respective acquisition date. Pro forma information is not presented as the operations of the acquired businesses are not significant compared to the overall operations of the Company.

The following table presents the purchase price allocation of the fair value of the acquisitions that occurred during the second quarter of 2012:

 

     (Dollars in millions)  

Assets

  

Current assets

   $ 4.7   

Property, plant and equipment

     1.3   

Intangible assets:

  

Intellectual property

     48.7   

In-process research and development (“IPR&D”)

     45.5   

Goodwill

     27.4   
  

 

 

 

Total assets acquired

     127.6   
  

 

 

 

Less:

  

Current liabilities

     4.7   

Deferred tax liabilities

     11.0   
  

 

 

 

Liabilities assumed

     15.7   
  

 

 

 

Net assets acquired

   $ 111.9   
  

 

 

 

The Company is continuing to evaluate the initial purchase price allocation as of the respective acquisition dates. Further adjustments may be necessary as additional information related to the fair values of assets acquired and liabilities assumed is assessed.

Certain assets acquired in the second quarter acquisitions qualify for recognition as intangible assets, apart from goodwill, in accordance with FASB guidance related to business combinations. The estimated fair values of intangible assets acquired include intellectual property of $48.7 million and IPR&D of $45.5 million. Intellectual property has useful lives ranging from 15 to 20 years, and IPR&D has an indefinite life and is not amortized until completion and development of the related project, at which time the IPR&D becomes an amortizable asset. If the related project is not completed in a timely manner, the Company may incur an impairment charge related to

 

9


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

the IPR&D, calculated as the excess of the asset’s carrying value over its fair value. The goodwill resulting from the acquisitions primarily reflects the expected revenue growth attributable to anticipated increased market penetration from future products and customers. Goodwill and the step-up in basis of the intangible assets are not deductible for tax purposes.

Note 4—Restructuring and other impairment charges

The amounts recognized in restructuring and other impairment charges for the three and six months ended July 1, 2012 and June 26, 2011 consisted of the following:

 

     Three Months Ended      Six Months Ended  
     July 1,
2012
     June 26,
2011
     July 1,
2012
    June 26,
2011
 
     (Dollars in thousands)  

2012 restructuring charges

   $ 265       $ —         $ 871      $ —     

2007 Arrow integration program

     56         115         (1,875     710   

Impairment charges

     —           3,061         —          3,061   
  

 

 

    

 

 

    

 

 

   

 

 

 

Restructuring and other impairment charges

   $ 321       $ 3,176       $ (1,004   $ 3,771   
  

 

 

    

 

 

    

 

 

   

 

 

 

2012 Restructuring Charges

During the three and six months ended July 1, 2012, the Company incurred restructuring charges of $0.3 million and $0.9 million, respectively, related to the termination of certain distributor agreements in Europe and a redesign of operations at our North America plants.

2011 Restructuring Program

During 2011, the Company initiated a restructuring program at three facilities to consolidate operations and reduce costs. During the six months ended July 1, 2012, no costs have been incurred related to this program. The Company expects to incur additional contract termination costs of approximately $2.7 million when it has completely exited a leased facility. All of the employee termination benefits will be paid in 2012. The payment of the lease contract termination costs will continue until 2015.

2007 Arrow Integration Program

In connection with the Company’s acquisition of Arrow International, Inc. (“Arrow”), the Company implemented a program in 2007 to integrate Arrow’s businesses into the Company’s other businesses. The aspects of this program that affect Teleflex employees and facilities (such aspects being referred to as the “2007 Arrow integration program”) are charged to earnings and classified as restructuring and impairment charges. The following table provides information relating to the charges associated with the 2007 Arrow integration program that were included in restructuring and other impairment charges in the condensed consolidated statements of income for the periods presented:

 

     Three Months Ended     Six Months Ended  
     July 1,
2012
     June 26,
2011
    July 1,
2012
    June 26,
2011
 
     (Dollars in thousands)  

Termination benefits

   $ —         $ 4      $ —        $ 11   

Facility closure costs

     56         (76     148        74   

Contract termination costs

     —           187        (2,023     625   
  

 

 

    

 

 

   

 

 

   

 

 

 
   $ 56       $ 115      $ (1,875   $ 710   
  

 

 

    

 

 

   

 

 

   

 

 

 

 

10


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

No impairment charges were recognized during the three and six month periods ended July 1, 2012 and June 26, 2011.

The following table provides information relating to changes in the accrued liability associated with the 2007 Arrow integration program during the six months ended July 1, 2012:

 

     Balance at
December 31,

2011
     Subsequent
Accruals
    Payments     Translation     Balance at
July  1,
2012
 
     (Dollars in thousands)  

Termination benefits

   $ 320       $ —        $ (5   $ (13   $ 302   

Facility closure costs

     —           148        (148     —          —     

Contract termination costs

     2,133         (2,023     —          (6     104   

Other restructuring costs

     21         —          —          —          21   
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 
   $ 2,474       $ (1,875   $ (153   $ (19   $ 427   
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

The reduction in the accrual for contract termination costs relates to a revised estimate for the settlement of a dispute involving the termination of a European distributor agreement that was established in connection with the acquisition of Arrow in 2007.

As of July 1, 2012, the Company expects future restructuring expenses associated with the 2007 Arrow integration program, if any, to be nominal.

Impairment Charges

During the second quarter of 2011, the Company recognized impairment charges of $3.1 million related to the decline in value of its investments in affiliates that are considered to be other than temporary. In making this determination, the Company considered multiple factors, including its intent and ability to hold investments, operating losses of investees that demonstrate an inability to recover the carrying value of the investments, the investee’s liquidity and cash position and level of market acceptance of the investee’s products and services.

Note 5—Impairment of goodwill

In 2012, the Company changed its North America reporting unit structure from a single reporting unit to five reporting units comprised of Vascular, Anesthesia/Respiratory, Cardiac, Surgical and Specialty. The Company allocated the assets and liabilities of the North America Segment among the new reporting units based on their respective operating activities, and then allocated goodwill among the reporting units using a relative fair value approach, as required by FASB Accounting Standards Codification Topic 350. The fair value of each reporting unit was determined based on a weighted combination of (i) estimation of the discounted cash flows of each of the reporting units based on projected earnings in the future (the income approach) and (ii) analysis of sales of similar assets in actual transactions (the market approach).

 

11


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

Following this allocation, the Company performed goodwill impairment tests on these new reporting units in the first quarter of 2012. As a result of these tests, the Company determined that three of the reporting units in the North America Segment were impaired, and it recorded goodwill impairment charges of $220 million in the Vascular reporting unit, $107 million in the Anesthesia/Respiratory reporting unit and $5 million in the Cardiac reporting unit in the first quarter of 2012.

Note 6—Inventories

Inventories as of July 1, 2012 and December 31, 2011 consisted of the following:

 

     July 1,
2012
    December 31,
2011
 
     (Dollars in thousands)  

Raw materials

   $ 82,528      $ 87,621   

Work-in-process

     45,341        45,486   

Finished goods

     186,694        198,587   
  

 

 

   

 

 

 
     314,563        331,694   

Less: Inventory reserve

     (30,008     (32,919
  

 

 

   

 

 

 

Inventories

   $ 284,555      $ 298,775   
  

 

 

   

 

 

 

Note 7—Goodwill and other intangible assets

In the first quarter of 2012, the Company changed its reporting structure to four reportable segments, three of which are geographically-based and one of which is comprised of the Company’s OEM business. See Note 14, “Business segment information” for additional information on the Company’s new reporting structure.

The following table provides information relating to changes in the carrying amount of goodwill, by reportable segment, for the six months ended July 1, 2012:

 

     North America
Segment
    EMEA Segment     AJLA Segment      OEM Segment     Total  
     (Dollars in thousands)  

Balance as of December 31, 2011

           

Goodwill

   $ 973,517      $ 283,362      $ 153,487       $ 28,176      $ 1,438,542   

Accumulated impairment losses

     —          —          —           —          —     
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 
     973,517        283,362        153,487         28,176        1,438,542   

Goodwill impairment charges

     (332,128     —          —           —          (332,128

Goodwill related to acquisitions

     26,733        687        —           —          27,420   

Goodwill transferred to assets held for sale

     —          —          —           (28,176     (28,176

Translation adjustment

     17        (10,868     784         —          (10,067

Transfer of goodwill

     679        (679     —           —          —     

Balance as of July 1, 2012

           

Goodwill

     1,000,946        272,502        154,271         —          1,427,719   

Accumulated impairment losses

     (332,128     —          —           —          (332,128
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 
   $ 668,818      $ 272,502      $ 154,271       $ —        $ 1,095,591   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

See Note 5 for discussion on the goodwill impairment charges.

 

12


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

The following table provides information, as of July 1, 2012 and December 31, 2011, regarding the gross carrying amount of, and accumulated amortization relating to, intangible assets:

 

     Gross Carrying Amount      Accumulated Amortization  
     July 1, 2012      December 31, 2011      July 1, 2012     December 31, 2011  
     (Dollars in thousands)  

Customer lists

   $ 532,780       $ 537,094       $ (128,335   $ (117,505 )

In-process research and development

     45,480         —           —          —     

Intellectual property

     253,221         221,171         (85,322     (85,402 )

Distribution rights

     16,245         16,669         (13,332     (13,484 )

Trade names

     317,519         322,404         (127     (1,160 )
  

 

 

    

 

 

    

 

 

   

 

 

 
   $ 1,165,245       $ 1,097,338       $ (227,116   $ (217,551 )
  

 

 

    

 

 

    

 

 

   

 

 

 

The increase in intangible assets during the six months ended July 1, 2012 primarily reflects the effect of the Company’s acquisitions. See Note 3 for discussion of Company’s acquisitions.

Amortization expense related to intangible assets was approximately $10.7 million for both the three months ended July 1, 2012 and June 26, 2011 and $21.2 million and $21.4 million for the six months ended July 1, 2012 and June 26, 2011, respectively. Estimated annual amortization expense for the remainder of 2012 and the next four succeeding years is as follows (dollars in thousands):

 

2012

   $ 21,900   

2013

     44,700   

2014

     42,100   

2015

     37,600   

2016

     37,500   

Note 8—Financial instruments

The Company uses derivative instruments for risk management purposes. Forward rate contracts are used to manage foreign currency transaction exposure. These derivative instruments are designated as cash flow hedges and are recorded on the balance sheet at fair market value. The effective portion of the gains or losses on derivatives is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. Gains and losses on the derivatives representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings. See Note 9, “Fair value measurement” for additional information.

 

13


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

The following table presents the location and fair values of derivative instruments designated as hedging instruments in the condensed consolidated balance sheet as of July 1, 2012 and December 31, 2011:

 

     July 1, 2012
Fair Value
     December 31, 2011
Fair Value
 
     (Dollars in thousands)  

Asset derivatives:

     

Foreign exchange contracts:

     

Other assets—current

   $ 572       $ 204   
  

 

 

    

 

 

 

Total asset derivatives

   $ 572       $ 204   
  

 

 

    

 

 

 

Liability derivatives:

     

Foreign exchange contracts:

     

Derivative liabilities—current

   $ 1,669       $ 633   
  

 

 

    

 

 

 

Total liability derivatives

   $ 1,669       $ 633   
  

 

 

    

 

 

 

The following table provides information as to the gains and losses attributable to derivatives in cash flow hedging relationships that were reported in other comprehensive income (“OCI”), and the location and amount of gains and losses attributable to such derivatives that were reclassified from accumulated other comprehensive income (“AOCI”) in the condensed consolidated statement of income for the three and six months ended July 1, 2012 and June 26, 2011:

 

     After Tax Gain/(Loss)
Recognized in OCI
 
     Three Months Ended     Six Months Ended  
     July 1,
2012
    June 26,
2011
    July 1,
2012
    June 26,
2011
 
     (Dollars in thousands)  

Interest rate swap

   $ 2,317      $ 1,694      $ 4,703      $ 3,351   

Foreign exchange contracts

     (471     (275     (397     (26
  

 

 

   

 

 

   

 

 

   

 

 

 

Total

   $ 1,846      $ 1,419      $ 4,306      $ 3,325   
  

 

 

   

 

 

   

 

 

   

 

 

 

 

     Pre-Tax (Gain)/Loss Reclassified
from AOCI into Income
 
     Three Months Ended     Six Months Ended  
     July 1,
2012
     June 26,
2011
    July 1,
2012
    June 26,
2011
 
     (Dollars in thousands)  

Interest rate swap:

         

Interest expense

   $ 3,643       $ 3,935      $ 7,394      $ 7,655   

Foreign exchange contracts:

         

Cost of goods sold

     130         (78     (767     (662

Income from discontinued operations

     —           (333     —          (768
  

 

 

    

 

 

   

 

 

   

 

 

 

Total

   $ 3,773       $ 3,524      $ 6,627      $ 6,225   
  

 

 

    

 

 

   

 

 

   

 

 

 

For the three and six months ended July 1, 2012 and June 26, 2011, there was no ineffectiveness related to the Company’s derivatives.

In 2011, the Company terminated its interest rate swap covering a notional amount of $350 million designated as a hedge against the variability of the cash flows in the interest payments under the Company’s term

 

14


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

loan. At July 1, 2012, the Company had $2.3 million, net of tax, recorded in AOCI associated with this interest rate swap, which will be amortized as interest expense over the remaining life of the original term of the hedged obligation, which expires in September 2012.

Based on interest rates and exchange rates at July 1, 2012, approximately $3.0 million of unrealized losses, net of tax, within AOCI are expected to be reclassified from AOCI during the next twelve months. However, the actual amount reclassified from AOCI could vary due to future changes in exchange rates.

Note 9—Fair value measurement

For a description of the fair value hierarchy, see Note 10 to the Company’s 2011 consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2011.

The following tables provide information regarding the financial assets and liabilities carried at fair value measured on a recurring basis as of July 1, 2012 and June 26, 2011:

 

     Total carrying
value at

July 1, 2012
     Quoted prices in
active markets
(Level 1)
     Significant other
observable inputs
(Level 2)
     Significant
unobservable
inputs (Level 3)
 
     (Dollars in thousands)  

Investments in marketable securities

   $ 4,535       $ 4,535       $ —         $ —     

Derivative assets

     572         —           572         —     

Derivative liabilities

     1,669         —           1,669         —     

Contingent consideration liabilities

     58,230         —           —           58,230   

 

     Total carrying
value at

June 26, 2011
     Quoted prices in
active markets
(Level 1)
     Significant other
observable inputs
(Level 2)
     Significant
unobservable
inputs (Level 3)
 
     (Dollars in thousands)  

Cash and cash equivalents

   $ 65,000       $ 65,000       $ —         $ —     

Bonds—foreign government

     6,915         6,915         —           —     

Investments in marketable securities

     4,209         4,209         —           —     

Derivative assets

     419         —           419         —     

Derivative liabilities

     19,128         —           19,128         —     

Contingent consideration liabilities

     9,530         —           —           9,530   

The following table provides information regarding changes in Level 3 financial liabilities during the periods ended July 1, 2012 and June 26, 2011:

 

     Contingent
consideration
 
     2012     2011  
     (Dollars in thousands)  

Beginning balance

   $ 9,676      $ —     

Initial estimate upon acquisition

     56,067        15,400   

Payment

     (7,000     (6,000

Revaluations

     (442     130   

Translation adjustment

     (71     —     
  

 

 

   

 

 

 

Ending balance

   $ 58,230      $ 9,530   
  

 

 

   

 

 

 

The carrying amount of long-term debt reported in the condensed consolidated balance sheet as of July 1, 2012 is $959.9 million. The Company uses a discounted cash flow technique that incorporates a market interest

 

15


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

yield curve with adjustments for duration, optionality, and risk profile to determine the fair value of its debt. The Company’s implied credit rating is a factor in determining the market interest yield curve. The following table provides the fair value of the Company’s debt by fair value hierarchy level as of July 1, 2012:

 

     Fair value of debt  
     (Dollars in millions)  

Level 1

   $ 730.7   

Level 2

     377.8   
  

 

 

 

Total

   $ 1,108.5   
  

 

 

 

During the first quarter of 2012, the Company recorded a goodwill impairment charge based on Level 3 inputs. See Note 5 for a discussion of the goodwill impairment.

Valuation Techniques

The Company’s financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to pay benefits under certain deferred compensation plans and other compensatory arrangements. The investment assets of the trust are valued using quoted market prices.

The Company’s financial assets valued based upon Level 2 inputs are comprised of foreign currency forward contracts. The Company’s financial liabilities valued based upon Level 2 inputs are comprised of an interest rate swap contract and foreign currency forward contracts. The Company uses forward rate contracts to manage currency transaction exposure and interest rate swaps to manage exposure to interest rate changes. The fair value of the foreign currency forward exchange contracts represents the amount required to enter into offsetting contracts with similar remaining maturities based on quoted market prices. The fair value of the interest rate swap contract is developed from market-based inputs under the income approach using cash flows discounted at relevant market interest rates. The Company has taken into account the creditworthiness of the counterparties in measuring fair value. The decrease in the Company’s derivative liabilities in 2012 is due to the termination of an interest rate swap agreement. See Note 8, “Financial instruments” for additional information.

The Company’s financial liabilities valued based upon Level 3 inputs are comprised of contingent consideration arrangements pertaining to the Company’s acquisitions. The fair value of contingent consideration is determined using a weighted probability of potential payment scenarios discounted at rates reflective of the Company’s credit rating and expected return on the acquired businesses. The assumptions used to develop the estimated amounts recognized for the contingent consideration arrangements are updated each reporting period. As of July 1, 2012, the Company has recorded approximately $17.5 million of contingent consideration in accrued expenses and the remaining $40.7 million in other liabilities.

Note 10—Changes in shareholders’ equity

In 2007, the Company’s Board of Directors authorized the repurchase of up to $300 million of outstanding Company common stock. Repurchases of Company stock under the Board authorization may be made from time to time in the open market and may include privately-negotiated transactions as market conditions warrant and subject to regulatory considerations. The stock repurchase program has no expiration date and the Company’s ability to execute on the program will depend on, among other factors, cash requirements for acquisitions, cash generated from operations, debt repayment obligations, market conditions and regulatory requirements. In addition, under the Company’s senior credit agreements, the Company is subject to certain restrictions relating to its ability to repurchase shares in the event the Company’s consolidated leverage ratio exceeds certain levels, which may limit the Company’s ability to repurchase shares under this Board authorization. Through July 1, 2012, no shares have been purchased under this Board authorization.

 

16


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

The following table provides a reconciliation of basic to diluted weighted average shares outstanding:

 

     Three Months Ended      Six Months Ended  
     July 1,
2012
     June 26,
2011
     July 1,
2012
     June 26,
2011
 
     (Shares in thousands)  

Basic

     40,834         40,536         40,801         40,297   

Dilutive shares assumed issued

     242         336         —           351   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted

     41,076         40,872         40,801         40,648   
  

 

 

    

 

 

    

 

 

    

 

 

 

Weighted average stock options that were antidilutive and therefore not included in the calculation of earnings per share were approximately 8,818 thousand and 8,999 thousand for the three and six month periods ended July 1, 2012, respectively, and approximately 8,776 thousand and 8,906 thousand for the three and six month periods ended June 26, 2011, respectively.

The following tables provide information relating to the changes in accumulated other comprehensive income (loss), net of tax, for the six months ended July 1, 2012 and June 26, 2011:

 

     Cash
Flow
Hedges
    Pension and
Other
Postretirement
Benefit Plans
    Foreign
Currency
Translation
Adjustment
    Accumulated
Other
Comprehensive
Income (Loss)
 
     (Dollars in thousands)  

Balance at December 31, 2011

   $ (7,257   $ (134,548   $ (17,548   $ (159,353

Current-period other comprehensive income (loss)

     4,306        2,336        (35,544     (28,902
  

 

 

   

 

 

   

 

 

   

 

 

 

Balance at July 1, 2012

   $ (2,951   $ (132,212   $ (53,092   $ (188,255
  

 

 

   

 

 

   

 

 

   

 

 

 

 

     Cash
Flow
Hedges
    Pension and
Other
Postretirement
Benefit Plans
    Foreign
Currency
Translation
Adjustment
    Accumulated
Other
Comprehensive
Income (Loss)
 
     (Dollars in thousands)  

Balance at December 31, 2010

   $ (15,262   $ (95,746   $ 59,128      $ (51,880

Current-period other comprehensive income

     3,340        5,619        61,840        70,799   

Divestiture of Marine

     —          8,427        (33,424     (24,997

Discontinued operations

     (15     (37     2,504        2,452   
  

 

 

   

 

 

   

 

 

   

 

 

 

Balance at June 26, 2011

   $ (11,937   $ (81,737   $ 90,048      $ (3,626
  

 

 

   

 

 

   

 

 

   

 

 

 

Note 11—Taxes on income from continuing operations

 

     Three Months Ended     Six Months Ended  
     July 1,
2012
    June 26,
2011
    July 1,
2012
    June 26,
2011
 

Effective income tax rate

     (0.6 )%      21.3     1.8     22.6

The effective income tax rate for the three months and six months ended July 1, 2012 was (0.6)% and 1.8% , respectively, compared to 21.3% and 22.6% for the three months and six months ended June 26, 2011, respectively. The decrease in the effective tax rate for the three months ended July 1, 2012 is primarily due to (i) a $7.7 million tax benefit on the settlement of foreign tax audits and (ii) an approximate $5.0 million reduction

 

17


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

in deferred tax liability resulting from a reduction in tax expense associated with potential future repatriation of non-permanently reinvested foreign earnings. In addition to the aforementioned items, the decrease in the effective tax rate for the six months ended July 1, 2012 was also impacted by a goodwill impairment charge recorded in the first quarter of 2012 for which only $45 million was tax deductible. Accordingly, the reduction in the tax rate for the six months ended July 1, 2012 reflects our inability to realize the full benefit of this charge.

Note 12—Pension and other postretirement benefits

The Company has a number of defined benefit pension and postretirement plans covering eligible U.S. and non-U.S. employees. The defined benefit pension plans are noncontributory. The benefits under these plans are based primarily on years of service and employees’ pay near retirement. The Company’s funding policy for U.S. plans is to contribute annually, at a minimum, amounts required by applicable laws and regulations. Obligations under non-U.S. plans are systematically provided for by depositing funds with trustees or by book reserves. In 2008 the Company amended the Teleflex Retirement Income Plan (“TRIP”) to cease future benefit accruals for all employees, other than those subject to a collective bargaining agreement and amended its Supplemental Executive Retirement Plans (“SERP”) for all executives to cease future benefit accruals for both employees and executives as of December 31, 2008. The Company replaced the non-qualified defined benefits provided under the SERP with a non-qualified defined contribution arrangement under the Company’s Deferred Compensation Plan, effective January 1, 2009. In addition, in 2008, the Company’s postretirement benefit plans were amended to eliminate future benefits for employees, other than those subject to a collective bargaining agreement, who had not attained age 50 and whose age plus service was less than 65.

The Company and certain of its subsidiaries provide medical, dental and life insurance benefits to pensioners and survivors. The associated plans are unfunded and approved claims are paid from Company funds.

Net benefit cost of pension and postretirement benefit plans consisted of the following:

 

     Pension
Three Months  Ended
    Postretirement Benefits
Three Months Ended
     Pension
Six Months Ended
    Postretirement Benefits
Six Months Ended
 
     July 1,
2012
    June 26,
2011
    July 1,
2012
     June 26,
2011
     July 1,
2012
    June 26,
2011
    July 1,
2012
     June 26,
2011
 
     (Dollars in thousands)  

Service cost

   $ 711      $ 613      $ 158       $ 198       $ 1,389      $ 1,192      $ 316       $ 396   

Interest cost

     4,125        4,342        473         549         8,251        8,586        946         1,100   

Expected return on Plan assets

     (5,042     (4,943     —           —           (10,085     (9,843     —           —     

Net amortization and deferral

     1,604        976        122         69         3,210        2,031        245         138   

Settlement charge

     (124     —          —           —           (124     —          —           —     

Curtailment charge

     111        —          —           —           111        —          —           —     
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

    

 

 

 

Net benefit cost

   $ 1,385      $ 988      $ 753       $ 816       $ 2,752      $ 1,966      $ 1,507       $ 1,634   
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

    

 

 

 

The increase in net amortization expense for the pension and postretirement benefit plans reflects the loss due to actuarial changes in benefit obligation recorded at December 31, 2011.

The Company is required to make minimum pension contributions totaling $19.5 million during 2012, of which $3.4 million and $11.3 million were made during the three and six months ended July 1, 2012, respectively.

 

18


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

Note 13—Commitments and contingent liabilities

Product warranty liability: The Company warrants to the original purchasers of certain of its products that it will, at its option, repair or replace such products, without charge, if they fail due to a manufacturing defect. Warranty periods vary by product. The Company has recourse provisions for certain products that would enable recovery from third parties for amounts paid under the warranty. The Company accrues for product warranties when, based on available information, it is probable that customers will make claims under warranties relating to products that have been sold, and a reasonable estimate of the costs (based on historical claims experience relative to sales) can be made. The following table provides information regarding changes in the Company’s product warranty liability accruals for the six months ended July 1, 2012 (dollars in thousands):

 

Balance—December 31, 2011

   $ 7,935   

Accruals for warranties issued in 2012

     50   

Settlements (cash and in kind)

     (6,275

Accruals related to pre-existing warranties(a)

     (1,253

Translation

     (2
  

 

 

 

Balance—July 1, 2012

   $ 455   
  

 

 

 

 

(a) Including those related to divested businesses. See Note 16, “Divestiture-related activities” for additional information.

Operating leases: The Company uses various leased facilities and equipment in its operations. The terms for these leased assets vary depending on the lease agreement. In connection with these operating leases, the Company had residual value guarantees in the amount of approximately $1.9 million at July 1, 2012. The Company’s future payments under the operating leases cannot exceed the minimum rent obligation plus the residual value guarantee amount. The residual value guarantee amounts are based upon the unamortized lease values of the assets under lease, and are payable by the Company if the Company declines to renew the leases or to exercise its purchase option with respect to the leased assets. At July 1, 2012, the Company had no liabilities recorded for these obligations. Any residual value guarantee amounts paid to the lessor may be recovered by the Company from the sale of the assets to a third party.

Environmental: The Company is subject to contingencies as a result of environmental laws and regulations that in the future may require the Company to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by the Company or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act (“CERCLA”), often referred to as Superfund, the U.S. Resource Conservation and Recovery Act (“RCRA”) and similar state laws. These laws require the Company to undertake certain investigative and remedial activities at sites where the Company conducts or once conducted operations or at sites where Company-generated waste was disposed.

Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory agencies and enforcement policies, as well as the presence or absence of other potentially responsible parties. At July 1, 2012, the Company’s condensed consolidated balance sheet included an accrued liability of approximately $9.1 million relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, potential liability may exceed the amount accrued as of July 1, 2012. The time frame over which the accrued amounts may be paid out, based on past history, is estimated to be 15-20 years.

 

19


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

Litigation: The Company is a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, intellectual property, employment and environmental matters. Based on information currently available, advice of counsel, established reserves and other resources, the Company does not believe that any such actions are likely to be, individually or in the aggregate, material to its business, financial condition, results of operations or liquidity. However, litigation is subject to many uncertainties, and the outcome of litigation is not predictable with assurance. An adverse outcome in current or future litigation could have a material adverse effect on the Company’s business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to expense in the period incurred.

Tax audits and examinations: The Company and its subsidiaries are routinely subject to tax examinations by various taxing authorities. As of July 1, 2012, the most significant tax examinations in process are in Canada, the Czech Republic, France and Austria. In conjunction with these examinations and as a regular and routine practice, the Company may determine a need to establish certain reserves or to adjust existing reserves with respect to uncertain tax positions. Accordingly, developments occurring with respect to these examinations, including resolution of uncertain tax positions, could result in increases or decreases to the Company’s recorded tax liabilities, which could impact the Company’s financial results.

Other: The Company has various purchase commitments for materials, supplies and items of permanent investment incident to the ordinary conduct of its business. On average, such commitments are not at prices in excess of current market.

Note 14—Business segment information

As a result of a reorganization of the Company’s internal business unit reporting structure and related internal financial reporting, effective January 1, 2012, the Company changed its segment reporting from a single operating segment to four operating segments.

An operating segment is a component of the Company (a) that engages in business activities from which it may earn revenues and incur expenses, (b) whose operating results are regularly reviewed by the Company’s chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance, and (c) for which discrete financial information is available. Based on these criteria, the Company has identified four operating segments, which also represent its four reportable segments.

Three of the four reportable segments are geographically based: North America, EMEA (representing the Company’s operations in Europe, the Middle East and Africa) and AJLA (representing the Company’s Asian and Latin American operations). The fourth reportable segment is OEM.

The Company’s geographically based segments design, manufacture and distribute medical devices primarily used in critical care, surgical applications and cardiac care and generally serve two end markets: hospitals and healthcare providers, and home health. The products of the geographically based segments are most widely used in the acute care setting for a range of diagnostic and therapeutic procedures and in general and specialty surgical applications. The Company’s OEM Segment designs, manufactures and supplies devices and instruments for other medical device manufacturers.

 

20


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

The following tables present the Company’s segment results for the three and six months ended July 1, 2012 and June 26, 2011:

 

     Three Months Ended July 1, 2012  
Segment Results    North
America
     EMEA      AJLA      OEM      Totals  
     (Dollars in thousands)  

Segment net revenues from external customers

   $ 160,357       $ 126,898       $ 60,097       $ 35,980       $ 383,332   

Segment depreciation and amortization

     14,963         5,346         1,411         1,059         22,779   

Segment operating profit(1)

     21,463         19,921         15,060         8,267         64,711   

Segment expenditures for property, plant and equipment

     7,602         3,677         231         3,292         14,802   

Intersegment revenues

     35,738         17,533         138         150      
     Three Months Ended June 26, 2011  
Segment Results    North
America
     EMEA      AJLA      OEM      Totals  
     (Dollars in thousands)  

Segment net revenues from external customers

   $ 156,516       $ 137,761       $ 54,693       $ 32,198       $ 381,168   

Segment depreciation and amortization

     15,968         6,034         1,444         957         24,403   

Segment operating profit(1)

     17,329         18,268         17,286         6,175         59,058   

Segment expenditures for property, plant and equipment

     5,119         2,570         338         1,175         9,202   

Intersegment revenues

     39,783         17,452         82         104      
     Six Months Ended July 1, 2012  
Segment Results    North
America
     EMEA      AJLA      OEM      Totals  
     (Dollars in thousands)  

Segment net revenues from external customers

   $ 327,665       $ 261,498       $ 107,085       $ 67,651       $ 763,899   

Segment depreciation and amortization

     29,813         10,847         2,824         1,964         45,448   

Segment operating profit(1)

     44,066         41,388         26,215         13,467         125,136   

Segment assets

     1,788,813         746,878         252,534         37,681         2,825,906   

Segment expenditures for property, plant and equipment

     11,441         6,372         238         6,493         24,544   

Intersegment revenues

     75,302         35,099         386         288      
     Six Months Ended June 26, 2011  
Segment Results    North
America
     EMEA      AJLA      OEM      Totals  
     (Dollars in thousands)  

Segment net revenues from external customers

   $ 309,240       $ 263,211       $ 96,726       $ 57,572       $ 726,749   

Segment depreciation and amortization

     31,924         11,660         2,925         1,834         48,343   

Segment operating profit(1)

     37,458         35,060         27,033         8,813         108,364   

Segment assets

     2,035,206         854,504         248,330         83,240         3,221,280   

Segment expenditures for property, plant and equipment

     8,540         3,984         387         2,067         14,978   

Intersegment revenues

     74,008         31,511         165         233      

 

(1) Segment operating profit includes a segment’s net revenues from external customers reduced by its cost of goods sold, selling, general and administrative expenses, and an allocation of corporate expenses. Segment operating profit excludes goodwill impairment charges, restructuring and impairment charges, gain on sales of business and assets, interest income and expense, loss on extinguishment of debt and taxes on income.

 

21


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

The following tables present reconciliations of segment results to the Company’s condensed consolidated results for the three and six months ended July 1, 2012 and June 26, 2011:

 

     Three Months Ended     Six Months Ended  
   July 1,
2012
    June 26,
2011
    July 1,
2012
    June 26,
2011
 
     (Dollars in thousands)  

Reconciliation of Segment Operating Profit to Income from Continuing Operations Before Interest, Loss on Extinguishments of Debt and Taxes

        

Segment operating profit

   $ 64,711      $ 59,058      $ 125,136      $ 108,364   

Goodwill impairment

     —          —          (332,128     —     

Restructuring and other impairment charges

     (321     (3,176     1,004        (3,771

Gain on sales of businesses and assets

     332        —          332        —     
  

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations before interest, loss on extinguishments of debt and taxes

   $ 64,722      $ 55,882      $ (205,656   $ 104,593   
  

 

 

   

 

 

   

 

 

   

 

 

 

 

     July 1, 2012      June 26, 2011  
     (Dollars in thousands)  

Reconciliation of Segment Assets to Condensed Consolidated Total Assets

     

Segment assets(1)

   $ 2,825,906       $ 3,221,280   

Corporate assets(2)

     727,026         541,492   

Assets of businesses divested(3)

     —           103,401   

Assets held for sale

     53,890         12,059   
  

 

 

    

 

 

 

Total assets

   $ 3,606,822       $ 3,878,232   
  

 

 

    

 

 

 

 

(1) Segment assets for the 2011 period include assets of the orthopedic business of the Company’s OEM Segment, which as July 1, 2012 are classified as held for sale.
(2) Increase in corporate assets from the prior period reflects higher cash balances as a result of the sale of businesses during the fourth quarter of 2011.
(3) Assets of businesses divested were previously reported as assets held for sale in 2011.

 

      Three Months Ended      Six Months Ended  
   July 1,
2012
     June 26,
2011
     July 1,
2012
     June 26,
2011
 
     (Dollars in thousands)  

Reconciliation of Segment Expenditures for Property, Plant and Equipment to Condensed Consolidated Total Expenditures for Property, Plant and Equipment

  

Segment expenditures for property, plant and equipment

   $ 14,802       $ 9,202       $ 24,544       $ 14,978   

Corporate expenditures for property, plant and equipment

     761         90         4,349         154   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total expenditures for property, plant and equipment

   $ 15,563       $ 9,292       $ 28,893       $ 15,132   
  

 

 

    

 

 

    

 

 

    

 

 

 

Note 15—Condensed consolidated guarantor financial information

In June 2011, Teleflex Incorporated (referred to below as “Parent Company”) issued $250 million of 6.875% senior subordinated notes through a registered public offering. The notes are guaranteed, jointly and severally, by certain of the Parent Company’s subsidiaries (each, a “Guarantor Subsidiary” and collectively, the

 

22


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

“Guarantor Subsidiaries”). The guarantees are full and unconditional, subject to certain customary release provisions. Each Guarantor Subsidiary is 100% owned by the Parent Company. The Company’s condensed consolidating statements of income and comprehensive income for the three and six month periods ended July 1, 2012 and June 26, 2011, condensed consolidating balance sheets as of July 1, 2012 and December 31, 2011 and condensed consolidated statements of cash flows for the six month periods ended July 1, 2012 and June 26, 2011, each of which are set forth below, provide consolidating information for:

 

  a. Parent Company, the issuer of the guaranteed obligations;

 

  b. Guarantor Subsidiaries, on a combined basis;

 

  c. Non-guarantor subsidiaries, on a combined basis; and

 

  d. Parent Company and its subsidiaries on a consolidated basis.

The same accounting policies as described in Note 1 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011 are used by each entity in the condensed consolidating financial information, except for the use by the Parent Company and Guarantor Subsidiaries of the equity method of accounting to reflect ownership interests in subsidiaries which are eliminated upon consolidation.

Consolidating entries and eliminations in the following consolidating financial statements represent adjustments to (a) eliminate intercompany transactions between or among the Parent Company, the Guarantor Subsidiaries and the Non-guarantor subsidiaries, (b) eliminate the investments in subsidiaries and (c) record consolidating entries.

 

23


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

TELEFLEX INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

 

     Three Months Ended July 1, 2012  
     Parent
Company
    Guarantor
Subsidiaries
    Non-Guarantor
Subsidiaries
    Eliminations     Condensed
Consolidated
 
     (Dollars in thousands)  

Net revenues

   $ —        $ 235,051      $ 204,785      $ (56,504   $ 383,332   

Cost of goods sold

     —          137,054        118,186        (56,272     198,968   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     —          97,997        86,599        (232     184,364   

Selling, general and administrative expenses

     12,929        59,789        32,580        653        105,951   

Research and development expenses

     —          12,012        1,690        —          13,702   

Restructuring and other impairment charges

     —          280        41        —          321   

Gain on sales of businesses and assets

     (116,194     —          (332     116,194        (332
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income from continuing operations before interest and taxes

     103,265        25,916        52,620        (117,079     64,722   

Interest expense

     36,626        (20,054     1,668        —          18,240   

Interest income

     (128     —          (378     —          (506
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income from continuing operations before taxes

     66,767        45,970        51,330        (117,079     46,988   

Taxes (benefit) on income from continuing operations

     (17,209     16,829        723        (621     (278

Equity in net income of consolidated subsidiaries

     (40,616     47,764        —          (7,148     —     
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income from continuing operations

     43,360        76,905        50,607        (123,606     47,266   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating income (loss) from discontinued operations

     (1,037     (9,265     2,253        —          (8,049

Taxes (benefit) on income (loss) from discontinued operations

     (290     (3,521     129        —          (3,682
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from discontinued operations

     (747     (5,744     2,124        —          (4,367
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     42,613        71,161        52,731        (123,606     42,899   

Less: Income from continuing operations attributable to noncontrolling interests

     —          —          286        —          286   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to common shareholders

     42,613        71,161        52,445        (123,606     42,613   

Other comprehensive loss attributable to common shareholders

     (62,945     (76,659     (62,453     139,112        (62,945
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive loss attributable to common shareholders

   $ (20,332   $ (5,498   $ (10,008   $ 15,506      $ (20,332
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

24


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

     Three Months Ended June 26, 2011  
     Parent
Company
    Guarantor
Subsidiaries
    Non-Guarantor
Subsidiaries
    Eliminations     Condensed
Consolidated
 
     (Dollars in thousands)  

Net revenues

   $ —        $ 236,923      $ 207,603      $ (63,358   $ 381,168   

Cost of goods sold

     —          145,465        115,389        (61,037     199,817   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     —          91,458        92,214        (2,321     181,351   

Selling, general and administrative expenses

     9,943        61,286        38,671        (62     109,838   

Research and development expenses

     —          10,056        2,399        —          12,455   

Restructuring and other impairment charges

     11        1,270        1,895        —          3,176   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations before interest, loss on extinguishments of debt and taxes

     (9,954     18,846        49,249        (2,259     55,882   

Interest expense

     27,879        (12,231     137        —          15,785   

Interest income

     (112     (18     (123     —          (253

Loss on extinguishments of debt

     816        —          —          —          816   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations before taxes

     (38,537     31,095        49,235        (2,259     39,534   

Taxes (benefit) on income (loss) from continuing operations

     (15,850     11,211        12,753        322        8,436   

Equity in net income of consolidated subsidiaries

     61,383        39,081        —          (100,464     —     
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income from continuing operations

     38,696        58,965        36,482        (103,045     31,098   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating income (loss) from discontinued operations

     (13,374     (569     10,350        —          (3,593

Taxes (benefit) on income (loss) from discontinued operations

     (8,748     (1,032     2,798        —          (6,982
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from discontinued operations

     (4,626     463        7,552        —          3,389   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     34,070        59,428        44,034        (103,045     34,487   

Less: Income from continuing operations attributable to noncontrolling interests

     —          —          258        —          258   

Income from discontinued operations attributable to noncontrolling interest

     —          —          159        —          159   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to common shareholders

     34,070        59,428        43,617        (103,045     34,070   

Other comprehensive income (loss) attributable to common shareholders

     16,164        (10,275     12,477        (2,202     16,164   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income attributable to common shareholders

   $ 50,234      $ 49,153      $ 56,094      $ (105,247   $ 50,234   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

25


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

    Six Months Ended July 1, 2012  
    Parent
Company
    Guarantor
Subsidiaries
    Non-Guarantor
Subsidiaries
    Eliminations     Condensed
Consolidated
 
    (Dollars in thousands)  

Net revenues

  $ —        $ 473,548      $ 409,706      $ (119,355   $ 763,899   

Cost of goods sold

    —          278,961        233,622        (117,162     395,421   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

    —          194,587        176,084        (2,193     368,478   

Selling, general and administrative expenses

    28,569        121,377        67,831        310        218,087   

Research and development expenses

    —          21,919        3,336        —          25,255   

Goodwill impairment

    —          331,779        349        —          332,128   

Restructuring and other impairment charges

    —          (1,650     646        —          (1,004

Gain on sales of businesses and assets

    (116,194     —          (332     116,194        (332
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations before interest and taxes

    87,625        (278,838     104,254        (118,697     (205,656

Interest expense

    73,101        (40,240     3,590        —          36,451   

Interest income

    (253     (8     (723     —          (984
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations before taxes

    14,777        (238,590     101,387        (118,697     (241,123

Taxes (benefit) on income (loss) from continuing operations

    (35,061     17,193        14,495        (903     (4,276

Equity in net income of consolidated subsidiaries

    (290,814     78,760        —          212,054        —     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations

    (240,976     (177,023     86,892        94,260        (236,847
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating income (loss) from discontinued operations

    (91     (9,429     2,400        —          (7,120

Taxes (benefit) on income (loss) from discontinued operations

    55        (3,584     171        —          (3,358
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from discontinued operations

    (146     (5,845     2,229        —          (3,762
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss)

    (241,122     (182,868     89,121        94,260        (240,609

Less: Income from continuing operations attributable to noncontrolling interests

    —          —          513        —          513   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) attributable to common shareholders

    (241,122     (182,868     88,608        94,260        (241,122

Other comprehensive loss attributable to common shareholders

    (28,902     (43,257     (34,766     78,023        (28,902
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss) attributable to common shareholders

  $ (270,024   $ (226,125   $ 53,842      $ 172,283      $ (270,024
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

26


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

     Six Months Ended June 26, 2011  
     Parent
Company
    Guarantor
Subsidiaries
    Non-Guarantor
Subsidiaries
    Eliminations     Condensed
Consolidated
 
     (Dollars in thousands)  

Net revenues

   $ —        $ 455,326      $ 389,461      $ (118,038   $ 726,749   

Cost of goods sold

     —          276,719        222,125        (115,493     383,351   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     —          178,607        167,336        (2,545     343,398   

Selling, general and administrative expenses

     19,324        118,947        72,683        594        211,548   

Research and development expenses

     —          19,433        4,053        —          23,486   

Restructuring and other impairment charges

     11        1,858        1,902        —          3,771   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations before interest, loss on extinguishments of debt and taxes

     (19,335     38,369        88,698        (3,139     104,593   

Interest expense

     58,084        (26,370     217        —          31,931   

Interest income

     (114     (41     (203     —          (358

Loss on extinguishments of debt

     15,413        —          —          —          15,413   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations before taxes

     (92,718     64,780        88,684        (3,139     57,607   

Taxes (benefit) on income (loss) from continuing operations

     (34,621     24,589        24,073        (1,032     13,009   

Equity in net income of consolidated subsidiaries

     195,873        112,120        —          (307,993     —     
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income from continuing operations

     137,776        152,311        64,611        (310,100     44,598   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating income (loss) from discontinued operations

     (51,318     39,589        72,846        —          61,117   

Taxes (benefit) on income (loss) from discontinued operations

     (25,424     5,583        12,875        —          (6,966
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from discontinued operations

     (25,894     34,006        59,971        —          68,083   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     111,882        186,317        124,582        (310,100     112,681   

Less: Income from continuing operations attributable to noncontrolling interests

     —          —          481        —          481   

Income from discontinued operations attributable to noncontrolling interest

     —          —          318        —          318   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to common shareholders

     111,882        186,317        123,783        (310,100     111,882   

Other comprehensive income attributable to common shareholders

     48,254        (23,420     28,912        (5,492     48,254   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss) attributable to common shareholders

   $ 160,136      $ 162,897      $ 152,695      $ (315,592   $ 160,136   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

27


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

TELEFLEX INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATING BALANCE SHEETS

 

     July 1, 2012  
     Parent
Company
     Guarantor
Subsidiaries
     Non-Guarantor
Subsidiaries
    Eliminations     Condensed
Consolidated
 
     (Dollars in thousands)  
ASSETS             

Current assets

            

Cash and cash equivalents

   $ 43,661       $ —         $ 501,330      $ —        $ 544,991   

Accounts receivable, net

     298         309,132         441,490        (475,754     275,166   

Inventories, net

     —           184,257         112,050        (11,752     284,555   

Prepaid expenses and other current assets

     5,618         3,985         15,210        —          24,813   

Prepaid taxes

     24,868         —           4,822        —          29,690   

Deferred tax assets

     5,974         24,938         6,034        (420     36,526   

Assets held for sale

     —           48,939         4,951        —          53,890   
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Total current assets

     80,419         571,251         1,085,887        (487,926     1,249,631   

Property, plant and equipment, net

     4,814         154,455         94,415        —          253,684   

Goodwill

     —           668,818         426,773        —          1,095,591   

Intangibles assets, net

     —           775,299         162,830        —          938,129   

Investments in affiliates

     5,028,619         1,067,840         20,189        (6,114,979     1,669   

Deferred tax assets

     68,877         —           2,206        (70,808     275   

Other assets

     40,517         2,555,041         161,707        (2,689,422     67,843   
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Total assets

   $ 5,223,246       $ 5,792,704       $ 1,954,007      $ (9,363,135   $ 3,606,822   
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 
LIABILITIES AND EQUITY             

Current liabilities

            

Current borrowings

   $ —         $ —         $ 4,700      $ —        $ 4,700   

Accounts payable

     80,859         390,475         73,012        (478,875     65,471   

Accrued expenses

     15,650         32,283         35,244        —          83,177   

Payroll and benefit-related liabilities

     27,847         7,389         23,685        —          58,921   

Derivative liabilities

     1,669         —           —          —          1,669   

Accrued interest

     9,149         —           6        —          9,155   

Income taxes payable

     —           —           12,911        —          12,911   

Current liability for uncertain tax positions

     —           —           3,910        —          3,910   

Deferred tax liabilities

     —           —           1,431        (420     1,011   

Liabilities held for sale

     —           1,750         (1     —          1,749   
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Total current liabilities

     135,174         431,897         154,898        (479,295     242,674   

Long-term borrowings

     959,945         —           —          —          959,945   

Deferred tax liabilities

     —           414,573         53,689        (70,808     397,454   

Pension and other postretirement benefit liabilities

     133,478         34,383         14,600        —          182,461   

Noncurrent liability for uncertain tax positions

     13,869         17,602         28,755        —          60,226   

Other liabilities

     2,291,310         56,432         416,841        (2,692,535     72,048   
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Total liabilities

     3,533,776         954,887         668,783        (3,242,638     1,914,808   

Total common shareholders’ equity

     1,689,470         4,837,817         1,282,680        (6,120,497     1,689,470   

Noncontrolling interest

     —           —           2,544        —          2,544   
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Total equity

     1,689,470         4,837,817         1,285,224        (6,120,497     1,692,014   
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Total liabilities and equity

   $ 5,223,246       $ 5,792,704       $ 1,954,007      $ (9,363,135   $ 3,606,822   
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

 

28


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

     December 31, 2011  
     Parent
Company
     Guarantor
Subsidiaries
     Non-Guarantor
Subsidiaries
     Eliminations     Condensed
Consolidated
 
     (Dollars in thousands)  
ASSETS              

Current assets

             

Cash and cash equivalents

   $ 114,531       $ —         $ 469,557       $ —        $ 584,088   

Accounts receivable, net

     269         304,813         464,834         (483,690     286,226   

Inventories, net

     —           201,147         107,188         (9,560     298,775   

Prepaid expenses and other current assets

     7,203         3,675         22,527         —          33,405   

Prepaid taxes

     24,006         —           4,869         (29     28,846   

Deferred tax assets

     8,659         26,886         5,883         (414     41,014   

Assets held for sale

     —           2,738         5,164         —          7,902   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Total current assets

     154,668         539,259         1,080,022         (493,693     1,280,256   

Property, plant and equipment, net

     8,208         149,300         94,404         —          251,912   

Goodwill

     —           1,001,353         437,189         —          1,438,542   

Intangibles assets, net

     —           711,962         167,825         —          879,787   

Investments in affiliates

     5,244,275         922,208         20,327         (6,184,802     2,008   

Deferred tax assets

     65,400         —           2,387         (67,509     278   

Other assets

     42,183         2,534,124         164,662         (2,669,649     71,320   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Total assets

   $ 5,514,734       $ 5,858,206       $ 1,966,816       $ (9,415,653   $ 3,924,103   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 
LIABILITIES AND EQUITY              

Current liabilities

             

Current borrowings

   $ —         $ —         $ 4,986       $ —        $ 4,986   

Accounts payable

     101,907         387,612         64,694         (487,121     67,092   

Accrued expenses

     23,208         25,407         29,545         —          78,160   

Payroll and benefit-related liabilities

     24,031         13,867         26,488         —          64,386   

Derivative liabilities

     633         —           —           —          633   

Accrued interest

     10,948         —           12         —          10,960   

Income taxes payable

     —           —           21,113         (29     21,084   

Current liability for uncertain tax positions

     —           —           22,656         —          22,656   

Deferred tax liabilities

     —           —           1,465         (415     1,050   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Total current liabilities

     160,727         426,886         170,959         (487,565     271,007   

Long-term borrowings

     954,809         —           —           —          954,809   

Deferred tax liabilities

     —           433,078         55,264         (67,509     420,833   

Pension and other postretirement benefit liabilities

     145,533         34,034         15,417         —          194,984   

Noncurrent liability for uncertain tax positions

     12,678         18,437         30,573         —          61,688   

Other liabilities

     2,260,399         5,583         443,875         (2,671,858     37,999   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Total liabilities

     3,534,146         918,018         716,088         (3,226,932     1,941,320   

Total common shareholders’ equity

     1,980,588         4,940,188         1,248,533         (6,188,721     1,980,588   

Noncontrolling interest

     —           —           2,195         —          2,195   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Total equity

     1,980,588         4,940,188         1,250,728         (6,188,721     1,982,783   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Total liabilities and equity

   $ 5,514,734       $ 5,858,206       $ 1,966,816       $ (9,415,653   $ 3,924,103   
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

 

29


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

TELEFLEX INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS

 

     Six Months Ended July 1, 2012  
     Parent
Company
    Guarantor
Subsidiaries
    Non-Guarantor
Subsidiaries
    Condensed
Consolidated
 
     (Dollars in thousands)  

Net cash (used in) provided by operating activities from continuing operations

   $ (76,757   $ 109,847      $ 56,148      $ 89,238   
  

 

 

   

 

 

   

 

 

   

 

 

 

Cash Flows from Investing Activities of Continuing Operations:

        

Expenditures for property, plant and equipment

     (4,349     (15,700     (8,844     (28,893

Proceeds from sales of businesses and assets, net of cash sold

     —          —          17,155        17,155   

Payments for businesses and intangibles acquired, net of cash acquired

     —          (59,334     (3,293     (62,627
  

 

 

   

 

 

   

 

 

   

 

 

 

Net cash (used in) provided by investing activities from continuing operations

     (4,349     (75,034     5,018        (74,365
  

 

 

   

 

 

   

 

 

   

 

 

 

Cash Flows from Financing Activities of Continuing Operations:

        

Decrease in notes payable and current borrowings

     —          (421     (286     (707

Proceeds from stock compensation plans

     4,091        —          —          4,091   

Dividends

     (27,756     —          —          (27,756

Intercompany transactions

     43,376        (33,555     (9,821     —     
  

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) financing activities from continuing operations

     19,711        (33,976     (10,107     (24,372
  

 

 

   

 

 

   

 

 

   

 

 

 

Cash Flows from Discontinued Operations:

        

Net cash (used in) provided by operating activities

     (9,475     1,284        —          (8,191

Net cash used in investing activities

     —          (2,121     —          (2,121
  

 

 

   

 

 

   

 

 

   

 

 

 

Net cash used in discontinued operations

     (9,475     (837     —          (10,312
  

 

 

   

 

 

   

 

 

   

 

 

 

Effect of exchange rate changes on cash and cash equivalents

     —          —          (19,286     (19,286
  

 

 

   

 

 

   

 

 

   

 

 

 

Net (decrease) increase in cash and cash equivalents

     (70,870     —          31,773        (39,097

Cash and cash equivalents at the beginning of the period

     114,531        —          469,557        584,088   
  

 

 

   

 

 

   

 

 

   

 

 

 

Cash and cash equivalents at the end of the period

   $ 43,661      $ —        $ 501,330      $ 544,991   
  

 

 

   

 

 

   

 

 

   

 

 

 

 

30


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

    Six Months Ended June 26, 2011  
    Parent
Company
    Guarantor
Subsidiaries
    Non-Guarantor
Subsidiaries
    Condensed
Consolidated
 
    (Dollars in thousands)  

Net cash (used in) provided by operating activities from continuing operations

  $ (78,062   $ 78,432      $ 37,403      $ 37,773   
 

 

 

   

 

 

   

 

 

   

 

 

 

Cash Flows from Investing Activities of Continuing Operations:

       

Expenditures for property, plant and equipment

    (154     (9,982     (4,996     (15,132

Proceeds from sales of businesses and assets, net of cash sold

    —          62,044        38,872        100,916   

Payments for businesses and intangibles acquired, net of cash acquired

    —          (30,570     —          (30,570
 

 

 

   

 

 

   

 

 

   

 

 

 

Net cash (used in) provided by investing activities from continuing operations

    (154     21,492        33,876        55,214   
 

 

 

   

 

 

   

 

 

   

 

 

 

Cash Flows from Financing Activities of Continuing Operations:

       

Proceeds from long-term borrowings

    515,000        —          —          515,000   

Repayment in long-term borrowings

    (455,800     —          —          (455,800

Debt and equity issuance and amendment costs

    (19,058     —          —          (19,058

Proceeds from stock compensation plans

    30,577        —          —          30,577   

Dividends

    (27,438     —          —          (27,438

Intercompany transactions

    192,478        (103,847     (88,631     —     
 

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) financing activities from continuing operations

    235,759        (103,847     (88,631     43,281   
 

 

 

   

 

 

   

 

 

   

 

 

 

Cash Flows from Discontinued Operations:

       

Net cash (used in) provided by operating activities

    (3,199     4,068        12,282        13,151   

Net cash used in investing activities

    (3     (145     (1,238     (1,386
 

 

 

   

 

 

   

 

 

   

 

 

 

Net cash (used in) provided by discontinued operations

    (3,202     3,923        11,044        11,765   
 

 

 

   

 

 

   

 

 

   

 

 

 

Effect of exchange rate changes on cash and cash equivalents

    —          —          9,324        9,324   
 

 

 

   

 

 

   

 

 

   

 

 

 

Net increase in cash and cash equivalents

    154,341        —          3,016        157,357   

Cash and cash equivalents at the beginning of the period

    22,632        —          185,820        208,452   
 

 

 

   

 

 

   

 

 

   

 

 

 

Cash and cash equivalents at the end of the period

  $ 176,973      $ —        $ 188,836      $ 365,809   
 

 

 

   

 

 

   

 

 

   

 

 

 

Note 16—Divestiture-related activities

When dispositions occur in the normal course of business, gains or losses on the sale of such businesses or assets are recognized in the income statement line item Gain on sales of businesses and assets. During the second quarter of 2012, the Company sold a building, with a net book value of zero, that had been classified as an asset held for sale and realized a gain of approximately $0.3 million.

 

31


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

Discontinued Operations

On July 18, 2012, the Company announced that it has entered into a definitive agreement to sell the orthopedic business of its OEM Segment to Tecomet for $45.2 million. The transaction is subject to certain regulatory approvals and other customary closing conditions and is expected to close by the end of the third quarter of 2012. The current and prior period income statements and cash flows have been revised to present the orthopedic business as discontinued operations. The July 1, 2012 balance sheet contains the net assets and net liabilities of the orthopedic business, net of assets and liabilities retained by the Company, in the assets and liabilities held for sale. The December 31, 2011 balance sheet has not been changed.

Additionally, the Company has recorded $1.2 million and $0.2 million of expense during the three and six months ended July 1, 2012, respectively, associated with retained liabilities related to businesses that have been divested.

On December 2, 2011, the Company completed the sale of its business units that design, engineer and manufacture air cargo systems and air cargo containers and pallets to a subsidiary of AAR CORP for $280.0 million in cash and realized a gain of $126.8 million, net of tax, from the sale. In the second quarter of 2012, the Company received an additional $16.8 million in proceeds as a working capital adjustment pursuant to the terms of the agreement related to the sale of the business, which resulted in recognizing an additional gain on sale of $2.2 million, net of tax. These business units represented the sole remaining businesses in the Company’s former Aerospace Segment.

On March 22, 2011, the Company completed the sale of its marine business to an affiliate of H.I.G. Capital, LLC for consideration of $123.1 million (consisting of $103.1 million in cash, plus a subordinated promissory note in the amount of $4.5 million and the assumption by the buyer of approximately $15.5 million in liabilities related to the marine business). Net assets transferred to the buyer in the sale included $1.5 million of cash, resulting in net cash proceeds to the Company of $101.6 million. The Company realized a gain of $57.3 million, net of tax benefits, from the sale of the business. As a result of the disposition, the Company realized accumulated losses from pension and postretirement obligations of approximately $8.4 million and cumulative translation gains of approximately $33.4 million as part of the gain on sale, resulting in a net change of approximately $25.0 million in accumulated other comprehensive income. The marine business consisted of the Company’s businesses that were engaged in the design, manufacture and distribution of steering and throttle controls and engine and drive assemblies for the recreational marine market, heaters for commercial vehicles and burner units for military field feeding appliances. The marine business represented the sole remaining business in the Company’s former Commercial Segment.

 

32


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

The following table presents the operating results of the operations that have been treated as discontinued operations for the periods presented:

 

     Three Months Ended     Six Months Ended  
     July 1,
2012
    June 26,
2011
    July 1,
2012
    June 26,
2011
 
     (Dollars in thousands)  

Net revenues

   $ 6,637      $ 63,417      $ 13,827      $ 158,893   

Costs and other expenses

     7,250        62,506        13,511        150,045   

Goodwill impairment(1)

     9,700        —          9,700        —     

Gain (loss) on disposition(2)

     2,264        (4,504     2,264        52,269   
  

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from discontinued operations before income taxes

     (8,049     (3,593     (7,120     61,117   

Provision for income taxes(3)

     (3,682     (6,982     (3,358     (6,966
  

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from discontinued operations

     (4,367     3,389        (3,762     68,083   

Less: Income from discontinued operations attributable to noncontrolling interest

     —          159        —          318   
  

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from discontinued operations attributable to common shareholders

   $ (4,367   $ 3,230      $ (3,762   $ 67,765   
  

 

 

   

 

 

   

 

 

   

 

 

 

 

(1) During the second quarter of 2012, the Company recognized a non-cash goodwill impairment charge of $9.7 million to adjust the carrying value of the orthopedic business to its estimated fair value.
(2) The $2.3 million pre-tax gain on disposition in 2012 reflects the gain recognized on the working capital adjustment in the second quarter related to the sale of the cargo systems and cargo container businesses.
(3) The provision for income taxes for the three and six months ended July 1, 2012 was impacted favorably by the realization of a tax benefit on impairment of goodwill. The provision for income taxes for the three months ended June 26, 2011 was impacted favorably by the realization of net tax benefits resulting from the resolution (including the expiration of statutes of limitation) of U.S. federal, state, and foreign tax matters relating to prior years. In addition, the provision for income taxes for the six months ended June 26, 2011 was further impacted favorably because taxes on the sale of the marine business were incurred at a rate that was significantly lower than the statutory tax rate.

 

33


Table of Contents

TELEFLEX INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

Assets and Liabilities Held for Sale

The table below provides information regarding assets and liabilities held for sale at July 1, 2012 and December 31, 2011. At July 1, 2012, the assets and liabilities held for sale included the Company’s orthopedic business and three buildings. These assets and liabilities are classified as current within the consolidated balance sheets as the Company expects these businesses to be sold within 12 months of July 1, 2012.

 

     July 1, 2012      December 31, 2011  
     (Dollars in thousands)  

Assets held for sale:

     

Accounts receivable, net

   $ 2,471       $ —     

Inventories, net

     7,514         —     

Other current assets

     41         —     

Property, plant and equipment, net

     17,050         7,902   

Goodwill

     18,476         —     

Intangible assets, net

     8,338         —     
  

 

 

    

 

 

 

Total assets held for sale

   $ 53,890       $ 7,902   
  

 

 

    

 

 

 

Liabilities held for sale:

     

Current liabilities

   $ 1,749       $ —     
  

 

 

    

 

 

 

Total liabilities held for sale

   $ 1,749       $ —     
  

 

 

    

 

 

 

 

34


Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

All statements made in this Quarterly Report on Form 10-Q, other than statements of historical fact, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “will,” “would,” “should,” “guidance,” “potential,” “continue,” “project,” “forecast,” “confident,” “prospects” and similar expressions typically are used to identify forward-looking statements. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about our business and the industry and markets in which we operate. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements due to a number of factors, including changes in business relationships with major customers or suppliers; demand for and market acceptance of new and existing products; our ability to integrate acquired businesses into our operations, realize planned synergies and operate such businesses profitably in accordance with expectations; our ability to effectively execute our restructuring programs; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; and global economic factors, including currency exchange rates and interest rates; difficulties entering new markets; and general economic conditions. For a further discussion of the risks relating to our business, see Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2011. We expressly disclaim any obligation to update these forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.

Overview

Teleflex is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. We primarily design, develop, manufacture and supply single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We sell our products to hospitals and healthcare providers in more than 130 countries through a combination of our direct sales force and distributors. Because our products are used in numerous markets and for a variety of procedures, we are not dependent upon any one end-market or procedure.

We categorize our products into four groups: Critical Care, Surgical Care, Cardiac Care and Original Equipment Manufacturer and Development Services (“OEM”). Critical Care, representing our largest product group, includes medical devices used in vascular access, anesthesia, urology and respiratory care applications; Surgical Care includes surgical instruments and devices; and Cardiac Care includes cardiac assist devices and equipment. OEM designs and manufactures instruments and devices for other medical device manufacturers.

Over the past several years we have focused on transitioning into a pure-play medical technology company through an extensive acquisition and divestiture program. We significantly changed the composition of our portfolio of businesses, expanding our presence in the medical technology industry, while divesting all of our businesses serving the aerospace and commercial markets, including the sale of our cargo systems and container businesses, a part of our former Aerospace Segment, on December 2, 2011 and the sale of our marine business, a part of our former Commercial Segment, on March 22, 2011. The cargo systems, cargo container and marine businesses are classified as discontinued operations in our 2011 condensed consolidated financial statements incorporated by reference herein.

We are focused on achieving consistent, sustainable and profitable growth by increasing our market share and improving our operating efficiencies through:

 

   

the development of new products and product line extensions;

 

   

the investment in new technologies and broadening their applications;

 

35


Table of Contents
   

the expansion of the use of existing products in existing markets, as well as in new geographic markets;

 

   

leveraging our direct sales force and distribution network with new products, manufacturing and distribution facility rationalization and achieving economies of scale as we continue to expand; and

 

   

the potential broadening of our product portfolio through select acquisitions, licensing arrangements and partnerships that enhance, extend or expedite our development initiatives or our ability to increase our market share.

During the second quarter of 2012, we completed four late-stage, innovative technology acquisitions to help position us for future growth. We also entered into an agreement to divest the orthopedics business line of our OEM Segment. See Note 3 to the condensed consolidated financial statements included in this report for a discussion of the acquisitions and see Note 16 to the condensed consolidated financial statements included in this report for a discussion of the disposition.

Our research and development initiatives focus on developing new, innovative products for existing and new therapeutic applications as well as enhancements to, and line extensions of, existing products. Our portfolio of existing products and pipeline of potential new products consist primarily of Class I and Class II devices, which require 510(k) clearance by the FDA for sale in the United States. We believe the 510(k) clearance reduces our research and development costs and risks, and typically results in a shorter timetable for new product introductions as compared to premarket approval, or PMA, process that would be required for Class III devices.

Change in Reporting Segments and Business Unit Structure

Effective January 1, 2012, we changed our segment reporting from a single reportable segment to four reportable segments. Three of the four reportable segments are geographically based and are presented as North America, EMEA (representing our operations in Europe, the Middle East and Africa) and AJLA (representing our Asian and Latin American operations). The fourth reportable segment is comprised of our OEM business. See Note 14 to the condensed consolidated financial statements included in this report for a discussion of the segments. In addition, in the first quarter of 2012, we changed the number of our reporting units. In 2011, we had six reporting units comprised of North America, EMEA, OEM, Japan, Asia Pacific and Latin America. In 2012, in addition to establishing a new North America segment, we established five reporting units in that segment: Vascular, Anesthesia/Respiratory, Cardiac, Surgical and Specialty. Due to the change in the reporting unit structure in North America, we were required to conduct a goodwill impairment test with respect to each of the North American reporting units in the first quarter of 2012, and determined that the goodwill of three of the reporting units was impaired. As a result, we recorded a goodwill impairment charge of $332 million in the first quarter of 2012. See Note 5 to the condensed consolidated financial statements included in this report for a discussion of the goodwill impairment.

Health Care Reform

On March 23, 2010 the Patient Protection and Affordable Care Act was signed into law. This legislation will have a significant impact on our business. For medical device companies such as Teleflex, the expansion of medical insurance coverage should lead to greater utilization of the products we manufacture, but this legislation also contains provisions designed to contain the cost of healthcare, which could negatively affect pricing of our products. In addition, commencing in 2013, the legislation imposes a 2.3% excise tax on sales of medical devices. We continue to prepare for the implementation of this tax and to evaluate its potential impact on our business in light of several uncertainties regarding its application. As we further prepare for implementation and as the taxing authorities clarify aspects of the application of the tax relevant to us, we will be in a better position to ascertain its impact on our business. We currently estimate the impact of the medical device excise tax will be approximately $15 million annually, beginning in 2013.

Results of Operations

Discussion of constant currency excludes the impact of translating the results of international subsidiaries at different currency exchange rates from year to year.

 

36


Table of Contents

Net Revenues

Information regarding net revenues by product group is provided in the following table.

 

     Three Months Ended      % Increase/ (Decrease)  
     July 1,
2012
     June 26,
2011
     Constant
Currency(1)
    Foreign
Currency
    Total
Change
 
     (Dollars in millions)                     

Critical Care

   $ 254.1       $ 253.6         4.4        (4.2     0.2   

Surgical Care

     72.5         72.9         3.8        (4.3     (0.5

Cardiac Care

     20.5         22.1         (2.3     (5.3     (7.6

OEM

     36.0         32.2         13.6        (1.9     11.7   

Other

     0.2         0.4         19.7        (7.8     11.9   
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Total net revenues

   $ 383.3       $ 381.2         4.7        (4.1     0.6   
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

 

       Six Months Ended        % Increase/ (Decrease)  
     July 1,
2012
     June 26,
2011
     Constant
Currency(1)
    Foreign
Currency
    Total
Change
 
     (Dollars in millions)                     

Critical Care

   $ 510.3       $ 490.7         6.8        (2.8     4.0   

Surgical Care

     145.2         137.9         8.2        (2.9     5.3   

Cardiac Care

     40.5         39.8         5.5        (3.9     1.6   

OEM

     67.7         57.6         18.9        (1.4     17.5   

Other

     0.2         0.7         (53.5     (4.8     (58.3
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Total net revenues

   $ 763.9       $ 726.7         7.9        (2.8     5.1   
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

 

(1) Constant currency is a non-GAAP financial measure that measures the change in net revenues between current and prior year periods by excluding the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The constant currency rate is calculated by translating the prior year’s local currency net revenues by the current year’s foreign currency exchange rates. Management believes this measure is useful to investors because it eliminates items that do not reflect our day-to-day operations. In addition, management uses this financial measure for internal managerial purposes, when publicly providing guidance on possible future results, and to assist in our evaluation of period-to-period comparisons. This financial measure may not be comparable to similarly titled measures used by other companies and is presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures.

Net revenues for the three months ending July 1, 2012 increased 0.6% to $383.3 million from $381.2 million for the three months ending June 26, 2011. The increase in net revenues was largely due to higher volume ($9.2 million), reflecting core growth, mostly in AJLA, OEM and EMEA, price increases (approximately $5.1 million) across all segments and new products (approximately $3.5 million) in North America, EMEA and OEM. These increases were largely offset by a $15.7 million unfavorable impact of foreign currency exchange rates in 2012. Net revenues for the six months ending July 1, 2012 increased 5.1% to $763.9 million from $726.7 million for the six months ending June 26, 2011. The $37.2 million increase in net revenues was largely due to higher volume (approximately $41.5 million), which benefited from six additional days in the 2012 fiscal period compared to 2011 and core growth in all segments, price increases (approximately $9.2 million) across all segments and new products (approximately $7.0 million) in North America, EMEA and OEM. These increases were partly offset by a $20.5 million unfavorable impact of foreign currency exchange rates in 2012.

Critical Care net revenues for the three months ending July 1, 2012 were $254.1 million, an increase of 0.2% over the corresponding prior year period. Excluding the impact of foreign currency exchange rates, net revenues increased 4.4% over the corresponding prior year period. The increase in net revenues was due to

 

37


Table of Contents

higher sales of anesthesia, vascular access and urology products. Critical Care net revenues for the six month period ending July 1, 2012 were $510.3 million, an increase of 4.0% over the corresponding prior year period. Excluding the impact of foreign currency exchange rates, net revenues increased 6.8% over the corresponding prior year period. The increase in net revenues was due to higher sales of vascular access, anesthesia, urology and respiratory products.

Surgical Care net revenues for the three months ending July 1, 2012 were $72.5 million, a decrease of 0.5% compared to the corresponding prior year period. Excluding the impact of foreign currency exchange rates, net revenues increased 3.8% over the corresponding prior year period. The increase in net revenues was due to higher sales of ligation and closure products, partly offset by a decline in sales of general surgical instruments and chest drainage products. Surgical Care net revenues for the six month period ending July 1, 2012 were $145.2 million, an increase of 5.3% over the corresponding prior year period. Excluding the impact of foreign currency exchange rates, net revenues increased 8.2% over the corresponding prior year period. The increase in net revenues was due to higher sales of ligation, general surgical instruments and closure products.

Cardiac Care net revenues for the three months ending July 1, 2012 were $20.5 million, a decrease of 7.6% compared to the corresponding prior year period. Excluding the impact of foreign currency exchange rates, net revenues decreased 2.3% compared to the corresponding prior year period. The decrease in net revenues was due to lower sales of intra-aortic balloon pumps and catheters. Cardiac Care net revenues for the six months ending July 1, 2012 were $40.5 million, a 1.6% increase over the corresponding prior year period. Excluding the impact of foreign currency exchange rates, net revenues increased 5.5% over the corresponding prior year period. The increase in net revenues was due to higher sales of intra-aortic pumps and catheters.

OEM net revenues for the three months ending July 1, 2012 were $36.0 million, an increase of 11.7% compared to the corresponding prior year period. Excluding the impact of foreign currency exchange rates, net revenues increased 13.6% over the corresponding prior year period. The increase in net revenues was due to higher sales of specialty suture and catheter fabrication products. OEM net revenues for the six months ending July 1, 2012 were $67.7 million, an increase of 17.5% over the corresponding prior year period. Excluding the impact of foreign currency exchange rates, net revenues increased 18.9% over the corresponding prior year period. The increase in net revenues was due to higher sales of specialty suture and catheter fabrication products.

Gross profit

 

     Three Months Ended     Six Months Ended  
     July 1,
2012
    June 26,
2011
    July 1,
2012
    June 26,
2011
 
     (Dollars in millions)  

Gross profit

   $ 184.4      $ 181.4      $ 368.5      $ 343.4   

Percentage of sales

     48.1     47.6     48.2     47.3

For the three and six month periods ending July 1, 2012, gross profit as a percentage of revenues increased 0.5% and 0.9%, respectively, compared to the corresponding periods of 2011, primarily due to price increases in all segments and lower manufacturing costs in North America and EMEA, partly offset by the unfavorable impact of foreign currency exchange rates, inventory write-offs for excess and slow moving product and damaged product in AJLA (approximately $2.8 million and $4.9 million for the three and six months ending July 1, 2012, respectively).

Selling, general and administrative

 

     Three Months Ended     Six Months Ended  
     July 1,
2012
    June 26,
2011
    July 1,
2012
    June 26,
2011
 
     (Dollars in millions)  

Selling, general and administrative

   $ 106.0      $ 109.8      $ 218.1      $ 211.5   

Percentage of sales

     27.6     28.8     28.5     29.1

 

38


Table of Contents

Selling, general and administrative expenses as a percentage of revenues for the three months ending July 1, 2012, decreased 1.2% compared to the corresponding period in 2011, due to a favorable impact from lower foreign currency exchange rates (approximately $6.3 million). In addition, selling, general and administrative expenses in 2011 included increases in litigation reserves of approximately $1.7 million and an increase in the valuation allowance against the zero coupon Greek government bonds (approximately $1.0 million) (the “Greek Bonds”) that we previously held. The comparative decreases in selling, general and administrative expenses as a percentage of revenues in the 2012 period were partly offset by increased sales and marketing costs (approximately $1.3 million), primarily in North America, EMEA and AJLA due to the higher sales volumes and support of new products, and higher general and administrative costs (approximately $1.1 million) across all segments. Selling, general and administrative expenses as a percentage of revenues for the six months ending July 1, 2012, decreased 0.6% compared to the corresponding period in 2011 due to a favorable impact from lower foreign currency exchange rates (approximately $6.6 million). In addition, selling, general and administrative expenses in 2011 included approximately $2.0 million of net separation costs for our former CEO (comprised of $5 million of payments under his employment agreement, less approximately $3 million of stock option and restricted share forfeitures), an increase in the valuation allowance against the Greek Bonds (approximately $1.2 million); the Greek Bonds were fully reserved at December 31, 2011, partly offset by increased sales and marketing costs (approximately $7.5 million), primarily in North America, EMEA and AJLA due to the higher sales volumes and support of new products, and higher general and administrative costs (approximately $5.7 million) across all segments.

Research and development

 

     Three Months Ended     Six Months Ended  
     July 1,
2012
    June 26,
2011
    July 1,
2012
    June 26,
2011
 
     (Dollars in millions)  

Research and development

   $ 13.7      $ 12.5      $ 25.3      $ 23.5   

Percentage of sales

     3.6     3.3     3.3     3.2

The increase in research and development expenses for the three and six month periods ending July 1, 2012, compared to the corresponding periods of 2011, principally reflects increased investments related to vascular products in North America and new technologies obtained in the second quarter of 2012 through acquisitions.

Interest expense

 

     Three Months Ended     Six Months Ended  
     July 1,
2012
    June 26,
2011
    July 1,
2012
    June 26,
2011
 
     (Dollars in millions)  

Interest expense

   $ 18.2      $ 15.8      $ 36.5      $ 31.9   

Average interest rate on debt

     4.1     5.0     4.2     5.1

The increase in interest expense for the three and six month periods ending July 1, 2012, compared to the corresponding periods of 2011, reflects higher average outstanding debt of approximately $68 million and $46 million, respectively, partly offset by lower average interest rates on debt.

Loss on extinguishments of debt

During the six months ended June 26, 2011, we recorded losses on the extinguishment of debt of $15.4 million as a result of the prepayment, in the first quarter of 2011, of our Senior Notes issued in 2004 (the “2004 Notes”) and our repayment, in the second quarter of 2011, of $125 million in term loan borrowings under our senior credit facility. In connection with the prepayment of our 2004 Notes, we recognized debt extinguishment costs of approximately $14.6 million relating to the prepayment “make-whole” amount of $13.9 million payable

 

39


Table of Contents

to the holders of the 2004 Notes and the write-off of $0.7 million of unamortized debt issuance costs incurred prior to the prepayment of the 2004 Notes. During the second quarter of 2011, we recorded a $0.8 million write-off of unamortized debt issuance costs as a loss on extinguishment of debt in connection with the $125 million repayment of the term loan borrowing.

Taxes on income from continuing operations

 

     Three Months Ended     Six Months Ended  
     July 1,
2012
    June 26,
2011
    July 1,
2012
    June 26,
2011
 

Effective income tax rate

     (0.6 )%      21.3     1.8     22.6

The effective income tax rate for the three months and six months ended July 1, 2012 was (0.6)% and 1.8% , respectively, compared to 21.3% and 22.6% for the three months and six months ended June 26, 2011, respectively. The decrease in the effective tax rate for the three months ended July 1, 2012 is primarily due to (i) a $7.7 million tax benefit on the settlement of foreign tax audits and (ii) an approximate $5.0 million reduction in deferred tax liability resulting from a reduction in tax expense associated with potential future repatriation of non-permanently reinvested foreign earnings. In addition to the aforementioned items, the decrease in the effective tax rate for the six months ended July 1, 2012 was also impacted by a goodwill impairment charge recorded in the first quarter of 2012 for which only $45 million was tax deductible. Accordingly, the reduction in the tax rate for the six months ended July 1, 2012 reflects our inability to realize the full benefit of this charge.

Restructuring and other impairment charges

 

     Three Months Ended      Six Months Ended  
     July 1,
2012
     June 26,
2011
     July 1,
2012
    June 26,
2011
 
     (Dollars in millions)  

Restructuring and other impairment charges

   $ 0.3       $ 3.2       $ (1.0   $ 3.8   

During the six months ended July 1, 2012, we reversed approximately $2.0 million of contract termination costs related to a settlement of a dispute involving the termination of a European distributor agreement that was established in connection with our acquisition of Arrow in 2007. This reversal was partly offset by $1.0 million of additional termination benefit costs, facility closure costs and contract termination costs primarily related to restructuring activities initiated at the beginning of 2012.

For additional information regarding our restructuring programs, see Note 4 to our condensed consolidated financial statements included in this report.

Segment Reviews

 

     Three Months Ended     Six Months Ended  
     July 1,
2012
     June 26,
2011
     %
Increase/
(Decrease)
    July 1,
2012
     June 26,
2011
     %
Increase/
(Decrease)
 
     (Dollars in millions)  

North America

   $ 160.3       $ 156.5         2.5      $ 327.6       $ 309.2         6.0   

EMEA

     126.9         137.8         (7.9     261.5         263.2         (0.6

AJLA

     60.1         54.7         9.9        107.1         96.7         10.7   

OEM

     36.0         32.2         11.7        67.7         57.6         17.5   
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

 

Segment net revenues

   $ 383.3       $ 381.2         0.6      $ 763.9       $ 726.7         5.1   
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

 

North America

   $ 21.5       $ 17.3         23.9      $ 44.1       $ 37.5         17.6   

EMEA

     19.9         18.3         9.0        41.4         35.1         18.0   

AJLA

     15.0         17.3         (12.9     26.2         27.0         (3.0

OEM

     8.3         6.2         33.9        13.4         8.8         52.8   
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

 

Segment operating profit(1)

   $ 64.7       $ 59.1         9.5      $ 125.1       $ 108.4         15.4   
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

 

 

40


Table of Contents
(1) See Note 14 of our condensed consolidated financial statements included in this report for a reconciliation of segment operating profit to income from continuing operations before interest, loss on extinguishments of debt and taxes.

The following is a discussion of our segment operating results.

Comparison of the three months and six months ended July 1, 2012 and June 26, 2011

North America

North America net revenues for the three months ending July 1, 2012, increased 2.5% compared to the corresponding period in 2011. The increase was due to price increases, primarily in Surgical and Vascular, new product sales, primarily in Vascular, and higher volume, primarily in Anesthesia/Respiratory. North America net revenues for the six months ending July 1, 2012, increased 6.0% compared to the corresponding period in 2011. The increase was due to higher volume of approximately $13.2 million, which benefited from six additional days in the 2012 fiscal period compared to 2011, price increases, primarily in Surgical and Vascular, and new product sales, primarily in Vascular and Anesthesia/Respiratory.

North America segment operating profit for the three and six month periods ending July 1, 2012 increased 23.9% and 17.6%, respectively, compared to the corresponding periods in 2011. The increase reflects the favorable impact of higher net revenues and lower manufacturing costs. These increases were partly offset by higher sales and marketing expenses, increased research and development costs and higher general and administrative expenses, primarily in support of new products and the technologies obtained in the second quarter of 2012 through acquisitions.

EMEA

EMEA net revenues for the three months ending July 1, 2012, decreased 7.9% compared to the corresponding period in 2011. The decrease reflects the unfavorable impact of lower foreign currency exchange rates (approximately $14.0 million), partly offset by higher volumes, new products and price increases. EMEA net revenues for the six months ending July 1, 2012 decreased 0.6% compared to the corresponding period in 2011. The decrease reflects the unfavorable impact of lower foreign currency exchange rates (approximately $18.6 million). The foreign currency exchange rate impact was largely offset by higher volume of approximately $14.4 million, which benefited from six additional days in the 2012 fiscal period compared to 2011, new product sales and price increases.

EMEA segment operating profit for the three and six month periods ending July 1, 2012, increased 9.0% and 18.0%, respectively, compared to the corresponding periods in 2011. The increase reflects the benefit of price increases and lower manufacturing costs. In addition, EMEA segment operating profit in 2011 included an increase in the valuation allowance against the Greek Bonds; the Greek Bonds were fully reserved at December 31, 2011. The comparative increase in segment operating profit in 2012 was partly offset by the unfavorable impact of lower foreign currency exchange rates and higher sales and marketing costs related to the higher volumes and new products.

AJLA

AJLA net revenues for the three months ending July 1, 2012, increased 9.9% compared to the corresponding period in 2011. The increase was due to higher volume, mostly due to sales growth in the Asia Pacific region, particularly in China, and price increases, partly offset by the unfavorable impact of foreign currency exchange rates. AJLA net revenues for the six months ending July 1, 2012, increased 10.7% compared to the corresponding period in 2011. The increase was due to higher volume of approximately $8.4 million, mostly due to sales growth in the Asia Pacific region, particularly in China, and six additional days in the 2012 fiscal period compared to 2011, and price increases, partly offset by the unfavorable impact of foreign currency exchange rates.

 

41


Table of Contents

AJLA segment operating profit for the three and six month periods ending July 1, 2012, decreased 12.9% and 3.0%, respectively, compared to the corresponding periods in 2011. The decrease reflects inventory write-offs for excess, slow moving and damaged product (approximately $2.8 million and $4.9 million in the three and six months ending July 1, 2012, respectively), higher operating expenses associated with the expansion of the sales force in China to support the revenue growth and the unfavorable impact of foreign currency exchange rates.

OEM

OEM net revenues for the three months ending July 1, 2012, increased 11.7% compared to the corresponding period in 2011. The increase was due to higher volume, price increases and new products. OEM net revenues for the six months ending July 1, 2012, increased 17.5% compared to the corresponding period in 2011. The increase was due to higher volume of approximately $6.8 million, which benefited from core growth and six additional days in the 2012 fiscal period compared to 2011, price increases and new products.

OEM segment operating profit for the three months ending July 1, 2012, increased 33.9% compared to the corresponding period in 2011. The increase reflects the higher net revenues, partly offset by higher manufacturing costs. OEM segment operating profit for the six months ending July 1, 2012, increased 52.8% compared to the corresponding period in 2011. The increase reflects the higher net revenues and lower manufacturing costs, partly offset by higher general and administrative costs.

Liquidity and Capital Resources

Cash Flows

Operating activities from continuing operations provided net cash of approximately $89.2 million during the first six months of 2012 compared to $37.8 million during the first six months of 2011. The $51.4 million increase is primarily due to favorable year-over-year changes in working capital items, primarily accounts receivable (favorable year-over-year by $23.7 million), inventory (favorable year-over-year by $20.8 million) and prepaid expenses and other current assets (favorable year-over-year by $12.2 million). The year-over-year improvement in working capital from accounts receivable reflects a significant collection of receivables from the Spanish government (approximately $17.5 million) during the second quarter of 2012, largely offset by higher net revenues in 2012 in North America and EMEA. The comparatively unfavorable change in accounts receivable in 2011 reflected the effect of the termination of a factoring agreement in Italy (approximately $19.2 million). The year-over-year improvement in working capital from inventories reflects a lower build-up of inventory and inventory write-offs for excess, slow moving and damaged product in AJLA in 2012. In contrast, 2011 increases in inventory reflected a planned worldwide build-up of inventory (approximately $11.8 million) to improve service levels by accelerating fulfillment of customer orders. The year-over-year improvement in working capital from prepaid expenses and other current assets primarily reflects the collection of outstanding VAT claims in 2012; these claims were accrued in 2011. These favorable year-over-year comparisons were partly offset by a $7.7 million non-cash adjustment to income taxes receivable and payable, net in settlement of foreign tax audits in 2012 and a reduction in deferred tax liability associated with potential future repatriation of non-permanently reinvested foreign earnings in 2012.

We currently do not foresee any difficulties in meeting our cash requirements or accessing credit as needed in the next twelve months. To date, we have not experienced an inordinate amount of payment defaults by our customers, and we have sufficient lending commitments in place to enable us to fund our anticipated additional operating needs. However, in light of the ongoing volatility in the domestic and global financial markets, we continue to monitor our credit risk related to countries affected by the sovereign debt issues in Europe, particularly Italy, Spain, Portugal and Greece. As of July 1, 2012, our net receivables from publicly funded hospitals in these countries were $74.4 million compared to $59.3 million as of June 26, 2011. For the six month periods ending July 1, 2012 and June 26, 2011, net revenues from Italy, Spain, Portugal and Greece were approximately 9% and 10%, respectively, of our total net revenues. As of July 1, 2012 and December 31, 2011,

 

42


Table of Contents

net trade receivables from these countries were approximately 39% and 38%, respectively, of our consolidated accounts receivable, net. If global economic conditions deteriorate, we may experience delays in customer payments and reductions in customer purchases. Moreover, we may incur higher credit losses related to the public hospital systems in these countries, which could have a material adverse effect on our results of operations and cash flows during the remainder of 2012 and in future years.

Net cash used in investing activities from continuing operations was $74.4 million during the first six months of 2012 reflecting payments for businesses acquired of $62.6 million and capital expenditures of $28.9 million, partly offset by the proceeds from sales of businesses and assets of $17.1 million. The payments for businesses acquired include $7 million for contingent consideration payments related to our acquisitions of VasoNova, Inc. (“VasoNova”) and Axiom Technology Partners LLC. The proceeds from sales of businesses and assets includes $16.8 million that we received as a working capital adjustment pursuant to the terms of the agreement related to the sale of the cargo systems and container businesses of our former Aerospace Segment, and proceeds of $0.3 million from the sale of a building that was included in our assets held for sale at a zero net book value. During the first six months of 2011, investing activities from continuing operations provided net cash of $55.2 million. In 2011, we received net cash proceeds of approximately $101.6 million from the sale of our marine business, partly offset by our acquisition of VasoNova for $30.6 million and capital expenditures of $15.1 million. The $30.6 million paid for the acquisition of VasoNova included the initial payment of $25 million plus a $6 million contingent payment made to the former VasoNova security holders upon receiving 510(k) clearance from the U.S. Food and Drug Administration related to a VasoNova product, less a hold back fee and cash in the business obtained in the acquisition. The increase in capital expenditures reflects plant expansion activities in OEM and increased investments in information technology systems.

We completed four acquisitions during the second quarter of 2012, consisting of two asset purchases and two stock purchases. The aggregate initial consideration we paid in connection with these acquisitions was approximately $55.8 million. As a result of these acquisitions, we acquired net assets of approximately $111.9 million, which included intangibles for technology, in-process research and development and goodwill of approximately $121.6 million. In addition, we recorded liabilities for contingent consideration arrangements related to each of the businesses acquired of approximately $56.1 million (see Note 3 to the condensed consolidated financial statements included in this report for a discussion of the acquisitions).

Net cash used in financing activities from continuing operations was $24.4 million in the first six months of 2012, primarily due to dividend payments of $27.8 million, compared to net cash provided by financing activities from continuing operations of $43.3 million in 2011. In 2011, we received proceeds from borrowings of $515 million, including the issuance of $250.0 million of 6.875% Senior Subordinated Notes. This additional indebtedness was partially offset by repayments of outstanding debt totaling $455.8 million, including the prepayment of the 2004 Notes totaling $165.8 million and the repayment of $125.0 million under our senior credit facility. We incurred debt extinguishment costs of $19.1 million associated with repayments of these amounts (including the related make whole amounts paid to the holders of the 2004 Notes and related fees). We also made dividend payments of $27.4 million and recognized proceeds of $30.6 million from the exercise of outstanding stock options issued under our stock compensation plans.

Stock Repurchase Program

In 2007, our Board of Directors authorized the repurchase of up to $300 million of our outstanding common stock. Repurchases of our stock under the Board authorization may be made from time to time in the open market and may include privately-negotiated transactions as market conditions warrant and subject to regulatory considerations. The stock repurchase program has no expiration date and our ability to execute on the program will depend on, among other factors, cash requirements for acquisitions, cash generated from operations, debt repayment obligations, market conditions and regulatory requirements. In addition, under our senior credit agreements, we are subject to certain restrictions relating to our ability to repurchase shares in the event our consolidated leverage ratio exceeds certain levels, which may limit our ability to repurchase shares under this Board authorization. Through July 1, 2012, no shares have been purchased under this Board authorization.

 

43


Table of Contents

The following table provides our net debt to total capital ratio:

 

     July 1, 2012     December 31, 2011  
     (Dollars in millions)  

Net debt includes:

    

Current borrowings

   $ 4.7      $ 5.0   

Long-term borrowings

     959.9        954.8   
  

 

 

   

 

 

 

Total debt

     964.6        959.8   

Less: Cash and cash equivalents

     545.0        584.1   
  

 

 

   

 

 

 

Net debt

   $ 419.6      $ 375.7   
  

 

 

   

 

 

 

Total capital includes:

    

Net debt

   $ 419.6      $ 375.7   

Total common shareholders’ equity

     1,689.5        1,980.6   
  

 

 

   

 

 

 

Total capital

   $ 2,109.1      $ 2,356.3   
  

 

 

   

 

 

 

Percent of net debt to total capital

     20     16

Our senior credit agreement and the indenture under which we issued our 6.875% senior subordinated notes due 2019 contain covenants that, among other things, limit or restrict our ability, and the ability of our subsidiaries, to incur debt, create liens, consolidate, merge or dispose of certain assets, make certain investments, engage in acquisitions, pay dividends on, repurchase or make distributions in respect of capital stock and enter into swap agreements. Our senior credit agreement also requires us to maintain a consolidated leverage ratio (generally, Consolidated Total Indebtedness to Consolidated EBITDA, each as defined in our senior credit agreement) of not more than 4.0:1 and a consolidated interest coverage ratio (generally, Consolidated EBITDA to Consolidated Interest Expense, each as defined in the senior credit agreement) of not less than 3.5:1 as of the last day of any period of four consecutive fiscal quarters calculated pursuant to the definitions and methodology set forth in the senior credit agreement. Non-recurring, non-cash charges, such as the goodwill impairment charge we recorded in the first six months of 2012, are excluded from the calculation of these ratios and, therefore, do not affect our compliance with these covenants.

We believe that our cash flow from operations, available cash and cash equivalents and our ability to access additional funds through credit facilities will enable us to fund our operating requirements, capital expenditures and debt obligations for the next 12 months and the foreseeable future. Depending on conditions in the capital markets and other factors, we will from time to time consider other financing transactions, the proceeds of which could be used to refinance current indebtedness or for other purposes.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

See the information set forth in Part II, Item 7A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011.

 

44


Table of Contents
Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are functioning effectively to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

(b) Change in Internal Control over Financial Reporting

No change in our internal control over financial reporting occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

45


Table of Contents

PART IIOTHER INFORMATION

 

Item 1. Legal Proceedings

We are a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, intellectual property, employment and environmental matters. Based on information currently available, advice of counsel, established reserves and other resources, we do not believe that any such actions are likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity.

 

Item 1A. Risk Factors

There have been no significant changes in risk factors for the quarter ended July 1, 2012. See the information set forth in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable.

 

Item 3. Defaults Upon Senior Securities

Not applicable.

 

Item 5. Other Information

Not applicable.

 

46


Table of Contents
Item 6. Exhibits

The following exhibits are filed as part of this report:

 

Exhibit
No.

       

Description

+10.1       Executive Employment Agreement, dated July 30, 2012, between Teleflex Medical Europe Limited and Liam Kelly.
+10.2       Senior Executive Officer Severance Agreement, dated July 30, 2012, between Teleflex Medical Europe Limited and Liam Kelly.
+10.3       Executive Change In Control Agreement, dated July 30, 2012 between Teleflex Incorporated and Liam Kelly.
  12.1       Computation of ratio of earnings to fixed charges.
  31.1       Certification of Chief Executive Officer, pursuant to Rule 13a–14(a) under the Securities Exchange Act of 1934.
  31.2       Certification of Chief Financial Officer, pursuant to Rule 13a–14(a) under the Securities Exchange Act of 1934.
  32.1       Certification of Chief Executive Officer, pursuant to Rule 13a–14(b) under the Securities Exchange Act of 1934.
  32.2       Certification of Chief Financial Officer, pursuant to Rule 13a–14(b) under the Securities Exchange Act of 1934.
101.1       The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended July 1, 2012, formatted in XBRL (eXtensible Business Reporting Language): (i) the Condensed Consolidated Statements of Income for the three and six months ended July 1, 2012 and June 26, 2011; (ii) the Condensed Consolidated Statements of Comprehensive Income for the three and six months ended July 1, 2012 and June 26, 2011; (iii) the Condensed Consolidated Balance Sheets as of July 1, 2012 and December 31, 2011; (iv) the Condensed Consolidated Statements of Cash Flows for the six months ended July 1, 2012 and June 26, 2011; (v) the Condensed Consolidated Statements of Changes in Equity for the six months ended July 1, 2012 and June 26, 2011; and (vi) Notes to Condensed Consolidated Financial Statements.

 

+ Indicates management contract or compensatory plan or arrangement.

 

47


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

TELEFLEX INCORPORATED
By:   /s/    BENSON F. SMITH        
 

Benson F. Smith

Chairman, President and Chief Executive Officer

(Principal Executive Officer)

By:   /s/    THOMAS E. POWELL        
 

Thomas E. Powell

Senior Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

Dated: July 31, 2012

 

48